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ABSTRACT 
Inducing high magnitude of antibodies with epitope breadth over prolonged periods of time is likely a 
prerequisite to prevent several of the world’s most serious infectious diseases such as HIV-1, malaria 
and tuberculosis for which there are no vaccines yet. A much better understanding of the innate 
immune mechanisms that are critical for inducing strong responses to vaccination is therefore 
essential. The overall aim of this thesis was to characterize early innate immune responses in vivo 
after administration of antigens. This includes studies of the recruitment of immune cell subsets to the 
site of antigen injection (e.g. skin or muscle), local cell activation and presence of inflammatory 
mediators, antigen uptake and transport and finally initiation of adaptive immunity in lymph nodes 
(LNs). To be able to approach this in humans in vivo, we first utilized skin punch biopsies collected 
from sites injected with purified protein derivate (PPD), which is a mixture of mycobacterial antigens 
used in the tuberculin skin test (TST). By performing tissue staining of cryosections we show in paper 
I that several subsets of dendritic cells (DCs), including the plasmacytoid DCs (PDCs) normally not 
residing in skin, infiltrated the dermis in the positive TST indurations, which was in contrast to donor-
matched saline-injected skin. The positive TST indurations were associated with cell death and high 
expression of the antimicrobial peptide LL37, which together can provide means for PDC activation 
and IFNα production. In line with this, IFN-inducible MxA was highly expressed in the positive TST 
sites. We expanded the studies in paper II and DC accumulation was also found in skin biopsies taken 
after skin tests using antigens from either mumps virus or Candida albicans. Further, TST indurations 
of HIV-1+ individuals also showed DC infiltration but to a lower degree, which likely reflect on the 
reduced integrity of their immune system. To this end, the level of DCs in the positive TST reactions 
correlated with the level of infiltrating T cells. 
The skin antigen tests represent recall of immunological memory responses locally. To enable studies 
of local innate immune activation after vaccine administration and priming of naïve responses, we 
developed a nonhuman primate (NHP) model in the second part of the thesis. After establishing and 
validating protocols for sample collection and tissue processing in paper III, we examined in paper IV 
how the distinct vaccine adjuvants; alum (benchmark), MF59 (emulsion) or alum with TLR7 agonist, 
influence the innate responses leading to adaptive immunity. HIV-1 envelope glycoprotein (Env) was 
administered as the vaccine antigen together with the adjuvants. We found a rapid infiltration of 
neutrophils, monocytes and DCs to the vaccine-injected muscle with all adjuvants. Env+ cells were 
readily detected in the muscle and draining LNs. In line with the finding of alum-TLR7 and MF59 
being superior over alum in terms of inducing both antibody- and T cell responses, alum consistently 
showed lower innate activation. While alum-TLR7 consistently induced robust DC maturation and 
type IFN I responses, MF59 induced neutrophil homing to LNs. Comparison of antigen presentation 
capacity of Env+ cells in the draining lymph nodes showed that myeloid DCs exceled at stimulating 
Env-specific CD4+ T cell responses. However, neutrophils were also capable of antigen presentation. 
Despite inducing different innate activation, both MF59 and alum-TLR7 enhanced the priming of 
Env-specific T cells in vaccine-draining LNs as well as increased the differentiation of T follicular 
helper cells and germinal center formations compared to alum. In summary, our findings demonstrate 
the initial immune events at the sites of antigen delivery, including vaccination in vivo. These early 
immunological responses shape the quantity and quality of adaptive immunity. Understanding the 
mechanisms by which distinct adjuvants influence vaccine response will help in the selection of the 
best-suited adjuvant to improve vaccine efficacy to a given pathogen. 
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PREFACE 
Vaccines are one of the most important discoveries in human medicine and have saved 
millions of people worldwide from death related to infectious diseases. Understanding the 
mechanisms of how vaccines work is vital for developing vaccines against severe diseases, to 
which no preventive vaccines currently exist. Vaccines stimulate the immune system, which 
consists of a remarkable variety of immune cells with unique features and functions. I am 
intrigued by how vaccines stimulate these immune cells and the sequential immunological 
events leading to protective immunity. 
In analogy with a light switch, vaccines “turn on” the immune system. 
So who is flipping on the light switch in the first place?  
Vaccines interact with the immune system for the first time at the site of delivery. The 
immune responses occurring directly after administration impact the generation of immunity. 
The main focus of my thesis has been the early immune responses following antigen delivery. 
The outline of the thesis starts with a brief historical introduction on vaccines followed by 
basic immunology of responses to non-self antigens including components of vaccines. A 
general overview on immune responses (especially those mediated by dendritic cells) is 
described, starting with the delivery or exposure of foreign antigens and ending with the 
generation of immunity. The introduction ends with brief description on HIV-1 infection and 
its vaccine development, plus the role of nonhuman primates as models for vaccination. 
Thereafter, the aims of the thesis and method description are presented. The main findings in 
the papers included in my thesis are presented and discussed in the results section. Finally, 
this thesis will end with concluding remarks, acknowledgements, references and reprints of 
the original papers. 
Stockholm, 2015-09-08         Frank Liang 
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1 INTRODUCTION 
1.1 HISTORY OF VACCINATION 
Vaccination is one of the most successful medical interventions implemented to prevent 
mortality. So far, vaccines have saved countless lives and remain essential for prevention of 
death due to infectious diseases worldwide (1, 2). One of the most important milestones in 
public health is the eradication of smallpox disease by a vaccine that was developed almost 
two centuries ago (3). Reports of vaccination go back to ancient China, where inoculation of 
dried pus, fluid or scabs from smallpox lesions into the skin or nasal cavity of healthy people 
resulted in protection against this fatal disease. However, while most of the inoculated 
individuals established protective smallpox immunity, some of them developed the disease 
instead (1, 2). By using substance from lesions caused by the milder cowpox disease for 
inoculation, Edward Jenner demonstrated in 1796 that protection against the much more 
severe smallpox disease was feasible without disease transmission. The beneficial effects of 
these inoculations were observed empirically and Jenner was likely unaware of the specific 
agent causing smallpox disease and the immune responses underlying smallpox immunity. A 
century later, Louis Pasteur and Robert Koch discovered that infectious diseases were caused 
by microbial pathogens. Subsequently, Pasteur used different strategies known as attenuation, 
to transform pathogens to vaccines by reducing their capacity to cause disease and yet retain 
the ability to generate immunity. Using the attenuation strategy, Pasteur and Roux generated 
the first human vaccine, which was a rabies vaccine (1). Based on Jenner and Pasteur’s 
empirical methods, i.e. using a pathogen strain closely related to the strain that causes severe 
disease in humans followed by the attenuation process, the vaccine against tuberculosis 
(Bacille Calmette Guérin, BCG) was subsequently generated. In fact, BCG is currently still 
the only clinical tuberculosis vaccine available, despite its suboptimal efficiency to protect 
from pulmonary disease.  
1.2 THE IMMUNOLOGY OF VACCINATION 
Vaccines are either preventive or therapeutic. While preventive vaccines inhibit initial 
infection, therapeutic vaccines induce immunity against existing disease. Either way, 
vaccination is aimed to stimulate the immune system to mount a response that protects and/or 
controls a disease. As during natural infection when pathogens breach the protective skin or 
mucosal barrier, vaccination also involve introduction of foreign substances. This triggers 
immune responses that lead to short-lived or lasting immunological memory (4). The immune 
system is divided into innate and adaptive immunity and has evolved to respond to pathogens 
by different defense mechanisms. While innate immune cells are quick to respond to 
pathogen invasion by a series of wide-range targeting molecules, adaptive immune cells 
confront the specific pathogen more precisely (5). The outcome of pathogenic insults is the 
generation of immunological memory, which is broadly defined as cell-mediated immunity 
(T cell responses) and humoral immunity (B cell responses). These series of events most 
likely recapitulates the fundamentals of early vaccine responses (4, 6). The type of adaptive 
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immune response as well as its quality and durability after infection or vaccination are 
dictated by the stimulation provided by the innate immune cells (2, 7). A more detailed 
understanding of the immune events leading to protective immunity would help the design of 
better vaccines.  
 
1.2.1 Sentinel cells of the innate immune system 
The immune system has physical, chemical, and cellular defense mechanisms against 
invasion by pathogens and foreign substances. The skin and mucosal tissues face the external 
environment and are constantly exposed to pathogens or foreign molecules. Thus, these 
tissues are armed with a large and complex network of innate immune cells that function as 
sentinels of innate immunity. This network consist of many different cells, including the 
resident phagocytic cells such as dendritic cells (DCs) and macrophages, which are 
professional antigen presenting cells (APCs) that scan the tissues for antigens of either self or 
non-self origin. Among the APCs, the DCs have the superior capacity to initiate and regulate 
adaptive immune responses (7-9). Vaccines such as the BCG vaccine and some influenza 
vaccines are delivered to the skin and the nasal cavity respectively and are likely to interact 
with these sentinel cells. Encounter of pathogens or foreign antigens like vaccine components 
activate innate cells, which subsequently initiate an array of functions to ultimately destroy 
pathogens as well as limit their infectivity and dissemination.  
 
1.2.2 Sensing of foreign antigens by innate immune cells 
The initiation of immune responses depends on the ability to sense the presence of foreign 
antigens. Pattern recognition receptors (PRRs) sense pathogen structures and products known 
as pathogen associated molecular patterns (PAMPs). The PRRs comprise the C-type lectin 
receptors (CLRs), NOD-like receptors (NLRs), stimulator of interferon genes (STING), RIG-
I-like receptors (RLRs) and toll-like receptors (TLRs) (9, 10).  
 
 
 
 
 
 
 
 
 
 
 
 
The TLRs bind to specific PAMPs such as pathogen-derived nuclei acids (TLR3, TLR7, 
TLR8, TLR9) or bacterial and fungal products (TLR1, TLR2, TLR4, TLR5, TLR6), which 
activates the immune cells. As discussed below, each type of innate immune cell expresses a 
distinct repertoire of TLRs (9-13).  
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Figure 1. Flow cytometer sorted 
human monocytes and neutrophils 
produce pro-inflammatory cytokine 
(TNF-α) and chemokine (MCP-1) 
after stimulation with TLR7/8 ligand. 
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The activation mediated by TLRs stimulates several immune functions for efficient pathogen 
elimination. These functions include production of different mediators like cytokines 
(molecules that activate and/or regulate cellular functions) and chemokines (molecules 
attracting cells towards a specific site) (Fig. 1). Capacity to present antigens and stimulate 
adaptive immune cells such as T cells and B cells are also enhanced in activated APCs (5). 
However, activation of immune cells can also occur in the absence of microbial PAMPs, e.g. 
during tissue injury or autoimmune disorders. Such “sterile inflammation” is mediated by 
danger associated molecular patterns (DAMPs), which include self-derived antigens such as 
antimicrobial peptides and nucleic acids (14). To this end, the innate immune cells are 
attractive targets in vaccine development since their activation through TLRs may potentially 
influence the quality of vaccine-induced immunity (6).  
 
1.2.3 Connecting innate immunity with adaptive immunity 
In general, efficient vaccines are defined by their ability to induce durable and protective 
adaptive immunity. The adaptive immune system recognizes a given pathogen by 
sophisticated recognition systems consisting of T cell receptors (TCRs) and B cell receptor 
(BCRs). Initially, T cells and B cells are less differentiated and referred to as naïve. In order 
for naïve T cells to fully carry out their effector functions against novel pathogens or 
antigens, they need to receive proper stimulation by innate immune cells (15). As described 
below, DCs are critical activators of naïve T cells through their high expression of co-
stimulatory molecules and major histocompatibility complex (MHC) loaded with processed 
antigen fragments (i.e. peptides), which are recognized by cognate TCRs. Extracellular 
proteins that are taken up by APCs are processed into peptides that are complexed with MHC 
class II molecules such as human leukocyte antigen (HLA)-DR. In contrast, intracellular 
proteins and those derived from intracellular pathogens are presented on MHC I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most vaccines are injected into the muscle but some are delivered to the dermis of the skin 
and the immunological events occurring after vaccine administration are likely similar to 
those induced during pathogen exposure (Fig. 2). It is believed that subsequent to vaccine 
Figure 2. Administration of intradermal versus intramuscular vaccines  
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delivery, DCs infiltrate the site of vaccine administration to capture antigens and become 
activated. Subsequently, activated DCs migrate to the draining lymph nodes (LNs) to prime 
naïve T cells via antigen presentation and co-stimulation, which leads to expansion of 
antigen-specific T cell clones and differentiation to different T helper (Th) cells (16, 17). 
However, vaccine antigens from the delivery site may also passively reach the LNs and be 
presented by LN-resident DCs (18). In simple terms, naïve CD4+ T cells primed via MHC II 
pathway yield Th1 or Th2 effectors cells. Several additional CD4+ Th cell subsets have been 
described, including Th17 cells involved in anti-bacterial and anti-fungal responses, T 
follicular helper (Tfh) cells mediating the augmentation of antibody responses (19) and T 
regulatory (Treg) cells with immune suppressive functions (17). In contrast, MHC class I 
presents antigens to CD8+ T cells, which differentiate into CTLs that kill infected cells or 
tumor cells. In this regard, vaccines that promote differentiation of Th1 helper cells and CTLs 
(cell-mediated response) are likely important for control of chronic infections and tumors (10, 
13). In contrast, the Th2 helper cells support antibody production (humoral response) by 
providing B cell stimulation.  Later on, some of the Th cells will become a part of the 
memory lymphocyte pool (20, 21).   
 
1.2.4 Considerations in vaccine development   
Most current vaccines work by inducing production of antibodies, which are the main 
effector molecules of the humoral immunity that target extracellular pathogens. Diseases such 
as diphtheria, tetanus, and measles are brought under control by vaccine-induced antibody 
responses. Intracellular pathogens such as human immunodeficiency virus (HIV)-1 would 
probably require both humoral and cell-mediated immunity to target free virus and infected 
cells respectively. Some of the challenges to establish preventive vaccines relate to the 
complexity of the pathogens in terms of their route of infection, life cycle and ability to 
escape immune responses (2). Desirable features of a vaccine include rapid generation of 
long lasting protection and the ability to induce the type of immune response that best 
eliminates the pathogen. An ideal vaccine should also induce protective immunity in 
immune-compromised individuals who are especially susceptible to infections. Elderly and 
young children may also need more efficient vaccines to compensate for reduced ability to 
mount robust immune responses. Importantly, vaccines need to have good safety and 
tolerability profiles while remaining potent to stimulate the immune system. The several 
challenges in vaccine development stress the need for a better understanding of how vaccines 
interact with the human immune system. Characterization of host-pathogen interactions and 
production of better recombinant vaccine antigens would also greatly contribute to improved 
design of vaccines against diseases to which no preventive vaccines currently exist, such as 
HIV-1, malaria and Ebola. In addition, understanding of how vaccine adjuvants stimulate 
immune responses that result in cell-mediated or humoral immunity or both, would help 
formulate vaccines that best target a given disease. 
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1.3 VACCINE ADJUVANTS 
1.3.1 The role of vaccine adjuvants  
Many of the existing vaccines consist of live attenuated or killed whole pathogens and 
thereby retain a high degree of similarity to the real pathogen in terms of microbial structures 
and contents. These vaccines have therefore inherent abilities to induce strong immune 
responses on their own (6). However, the inactivated polio vaccine and attenuated BCG 
vaccine are relatively inefficient despite containing intrinsic PAMPs. Further, attenuated 
vaccines that are in most cases efficient and safe can be precarious due to the risk of live 
attenuated vaccine strain to regain original virulence (2, 4). Furthermore, live attenuated 
pathogens are also not suitable for vaccinating immune-compromised individuals (4). To 
improve safety profiles, many of the licensed vaccines are non-live subunit vaccines that 
consist of specific proteins or capsular polysaccharides (3), which correspond to those found 
on the pathogens. These antigens are selected based on the efficiency and versatility of the 
adaptive immunity they are able to induce. Recombinant technologies in vaccine 
development have enabled production of scalable amounts of highly purified proteins for 
subunit vaccines. These vaccines lack PAMPs such as nucleic acids and other pathogenic 
components with intrinsic capacity to induce strong immune responses (22). Since activation 
of innate immune responses is a prerequisite for generating immunological memory, protein 
subunit vaccines are formulated together with an adjuvant to enhance their immune-
stimulatory properties. In fact, the word adjuvant comes from the Latin verb adjuvare 
meaning “to help”. Since adjuvants amplify immune responses, their immune stimulatory 
properties can also result in dose sparing which means that less amount of the vaccine antigen 
per vaccination and/or fewer vaccinations can be used without compromising the quantity 
and quality of subsequent immune memory (13).  
 
Adjuvants can be broadly divided into delivery systems, immune potentiators and adjuvant 
systems i.e. combination of adjuvants (2, 23-25).  Many novel adjuvants are in pre-clinical 
studies or clinical trials and include; oil-in-water emulsions, cytokines, bacterial toxins, 
polymeric microparticles, liposome-based adjuvants, polysaccharides, TLR agonists, 
saponin-based molecules and combinations thereof. Currently, there are only a few adjuvants 
approved for human vaccines. Alum, emulsions and virosomes (liposome-based adjuvant) are 
referred to as delivery systems since co-delivery of protein antigens with these adjuvants 
greatly enhance cellular antigen uptake compared to when protein antigens are administered 
alone (13, 26). Increased antigen uptake likely leads to better antigen presentation. However, 
delivery systems can also induce immune activation although they are not believed to directly 
target and activate specific immune cells by specific PRRs. In contrast, it is well established 
that monophosphoryl lipid A (MPL) derived from bacterial cell wall component called 
lipopolysaccharide (LPS) targets and activates cells via TLR4. Combination of the immune 
potentiator MPL and alum (AS04) is currently licensed for vaccines against hepatitis B virus 
as well as human papilloma viruses that cause cervical cancer.  
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The quantity, quality and durability of the generated immune responses set the criteria for 
vaccine efficacy, and how adjuvants enhance these criteria is of great interest in vaccine 
development. For example, adjuvants that induce high antibody levels may enable quicker 
pathogen clearance and mutation-prone pathogens could be more efficiently targeted if the 
adjuvants induced antibodies with broad specificity. However, the efficacy of a vaccine may 
also depend on adjuvants capable of inducing both humoral and cell-mediated immunity. 
How adjuvants work is not fully understood but some are thought to activate immune 
responses by mimicking the effects of PAMPs (2, 6), and/or enhance the functionality of both 
innate or adaptive immune cells, or prolong the persistence of the administrated vaccine in 
vivo (depot effect) and thereby extending the time for vaccines to interact with immune-
competent cells (27). Recently, considerable efforts have been focused on understanding the 
mechanisms of action of adjuvants. Indeed, strategies in vaccine development include 
formulating vaccine antigens with suitable adjuvant(s), which induces immune responses that 
best target the specific disease with improved efficiency, while remaining safe and tolerable. 
 
1.3.2 Aluminum adjuvants  
The most commonly used clinical adjuvant is based on different insoluble aluminum salts 
(aluminum hydroxide or aluminum phosphate), commonly referred to as alum. Alum has 
been used for almost 70 years in licensed vaccines. The vaccine antigens are adsorbed to 
alum by electrostatic forces, where negatively charged antigens adhere to the aluminum 
hydroxide while positively charged antigens are better attached to aluminum phosphate (27). 
Alexander T Glenny discovered alum already in 1926. Alum mainly enhances antibody-
based vaccine responses and thereby suitable for targeting extracellular pathogens, which are 
vulnerable for antibody-mediated immune responses. Despite being extensively used, the 
mechanisms behind alum’s adjuvant effect remains incompletely understood. It has been 
proposed that alum causes a depot effect as described above. It has also been suggested that 
adsorbing vaccine protein antigens to alum facilitates antigen uptake since the antigen 
become particulate. Recently, several mouse studies suggested that alum induces 
inflammation at the delivery site by engaging different pathways dependent on TLR signaling 
(28). However, there are also reports showing that TLRs are not involved (29) and that alum 
causes release of metabolites due to cell damage that activates other cells (30). Despite the 
unclear mechanism of action, alum is by far the most clinically used adjuvant and it induces 
sufficient responses for many vaccines and has an exceptional safety profile. However, alum 
mainly induces antibody responses, which may not be sufficient to clear e.g. intracellular 
pathogens. Intense research is currently pursued to develop new adjuvants that are able to 
induce better antibody- as well as cell-mediated immune responses. 
1.3.3 Emulsion adjuvants 
Distinctly different from alum are the emulsion adjuvants based on water and oil mixtures. 
Emulsion adjuvants exist as a “water-in-oil” emulsion when aqueous droplets are dispersed 
within an oily media and when the opposite is formulated, it is called “oil-in-water” 
emulsion. The earliest report on an emulsion used as an adjuvant was reported by Jules T 
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Freund in 1937 and this empirically discovered adjuvant is commonly known as Freund’s 
adjuvant (31). Freund’s adjuvant consists of paraffin oil plus surfactant and when killed 
mycobacteria are included, it is referred to as complete Freund’s adjuvant (CFA) (10). 
Although CFA has been shown to be efficient in stimulating both humoral and cell-mediated 
immunity, this emulsion adjuvant is not approved for human vaccines since it causes painful 
and harmful reactions at the injection site (10, 23, 31). In contrast, highly refined and well-
characterized oil-in-water emulsion adjuvants such as MF59 and AS03 are well tolerable and 
are licensed for pandemic influenza vaccines (10, 32, 33). Both of these emulsions are based 
on squalene, a precursor molecule to natural cholesterol that is more readily metabolized than 
paraffin oil in CFA (10, 33), which may explain why these adjuvants have better safety 
profiles. The other components in MF59 consist of surfactants that enable dispersion of 
approximately 160 nm wide squalene droplets within the aqueous citrate buffer. In addition to 
surfactants, the AS03 emulsion also contains α-tocopherol (vitamin E), which has immune 
enhancing properties (34).  
 
Nearly 100 million doses of MF59 have been commercially distributed and its safety profile 
has been extensively assessed (33). Influenza vaccine given together with MF59 has proven 
to be effective and safe among the elderly and young children, which are especially at risk for 
influenza-related fatality and do not respond well to traditional influenza vaccines due to their 
insufficient capacity to mount strong immune responses. In fact, several studies based on 
large cohorts of elderly participants, infants and young children show that MF59 significantly 
increased the efficacy of influenza vaccines and the generated antibodies had broad 
specificity (33). Since influenza virus mutates frequently, the broadened specificity of 
antibodies induced by the vaccine is particularly important. Especially since the vaccine is 
based on strains predicted to cause disease, which mean that the degree of protection is likely 
related to the cross-reactivity of the vaccine-induced antibodies. Moreover, dose sparing was 
observed in MF59-adjuvanted pandemic influenza vaccine since it induced protective 
antibody levels with lower antigen doses and fewer immunizations (33). How MF59 
stimulates immune responses is largely unclear and is thought to induce a so-called 
“immunocompetent environment” that facilitates innate immune events such as infiltration of 
immune cells and expression of molecules involved in cellular activation, migration and 
antigen presentation (33, 35). 
 
1.3.4 TLR agonist-based adjuvants 
In contrast to alum and MF59, which mainly enhance antibody responses, immune 
potentiators have the potential to activate cell-mediated immune responses. While the 
mechanisms of action of alum and emulsion adjuvants are largely unclear, the actions of 
immune potentiators are directly related to activation of specific PRRs such as the TLRs (10, 
13). Most immune potentiators are TLR agonists but so far, only MPL is approved. MPL is 
chemically removed of the toxic properties of LPS and activates immune cells like DCs by 
binding to TLR4 (Table 1). Other adjuvants in clinical trial that involve TLR stimulation are 
CpG DNA and Imidazoquinolines, which are agonists for TLR9 and TLR7/8 respectively 
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and these adjuvants enhance both cell-mediated and humoral immunity as well as promote 
sustained immune responses (10, 23, 24, 32). Importantly, the TLR7 agonist Imiquimod that 
is licensed as topical therapy for genital warts was shown to induce higher antibody responses 
in elderly participants of an influenza vaccine trial where intradermal immunization was 
given immediately after applying Imiquimod on the skin of the injection area (36).  Since 
TLR7 agonist is already implemented as a topical treatment in the clinic, their approval for 
use in human vaccines may be facilitated. 
 
 
 
 
 
 
 
 
 
 
 
 
However, TLR agonists are usually co-formulated with delivery systems such as alum since 
immune potentiators are small molecules that diffuses rapidly from the site of delivery (24). 
Using combinations of adjuvants may enable cellular activation via multiple innate receptors, 
which could be more effective than activating a single pathway (10). Nevertheless, immune 
responses initiated by a single pathway may in turn activate other pathways and/or activate 
adjacent immune cells in a bystander manner. Adjuvant systems have been shown to alleviate 
several challenges in vaccine development by eliciting effective immunity against complex 
pathogens. As reported in malaria vaccine trials, MPL plus a saponin-derived molecule 
(QS21) together with either an oil-in-water emulsion or liposomes induced increased 
protection via enhanced antibody and cell-mediated responses compared to alum alone as 
adjuvant (10, 23). Recently, a small molecule TLR7 agonist adsorbed to alum has shown 
potent adjuvanticity, which demonstrates the benefits of combination adjuvants (24, 37).  
 
 
1.4 THE EARLY IMMUNE RESPONSES AFTER ANTIGEN DELIVERY 
1.4.1 Recruitment of antigen presenting cells to antigen delivery sites 
Recruitment of DCs to the site of antigen exposure and internalization of antigen by these 
cells are thought to be essential in the generation of adaptive immune responses and control 
of immunity (7, 8, 38, 39). This is most likely the case for development of responses to 
vaccines too. However, recruitment of adjacent tissue-resident immune cells or from the 
circulation (e.g. neutrophils, monocytes and blood DCs) require inflammation and one of the 
earliest innate responses in tissues exposed to foreign material like whole pathogens, non-self 
antigens or vaccines, is the secretion of cytokines and chemokines. DCs are found in blood 
and at body surfaces such as the skin and mucosal tissues as well as lymphoid tissues. Thus, 
the dense population of DCs residing in skin is optimally located for exposure to intradermal 
vaccines (40), which could mean that they can readily take up vaccine antigens and rapidly 
………………….. TLR1 TLR2 TLR3 TLR4 TLR5 TLR6 TLR7 TLR8 TLR9 
CD1c+ MDCs          
CD141+ MDCs          
CD16+ MDCs          
PDCs          
Table1. TLR expressed by blood DCs, where the level of expression is indicated accordingly:  
Black (+ + +), dark grey (+ +), medium grey (+) light grey (+/–) and white (–)  
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become activated by the vaccine itself or the vaccine-induced inflammatory milieu. 
Chemokines and cytokines secreted by recruited cells may in turn recruit and activate other 
immune cells. In contrast to the skin, muscle tissue contains relatively few resident APCs 
(41) and infiltrating immune cells from the circulation such as DCs are likely those that 
mainly interact with intramuscular vaccines (6, 42). In this regard, upregulation of 
chemokines and cytokines in the adjuvant-injected muscle has been reported in mice (35).  
 
1.4.2 Non-classical and atypical antigen presenting cells 
Although DCs are critical for priming of naïve immune responses, mouse studies show that 
non-classical innate immune cells and atypical non-hematopoietic cells are also able to 
present antigens (43). The atypical APCs include non-hematopoietic cells such as epithelial, 
endothelial, stromal and skeletal muscle cells and are likely the initial producers of cytokines 
and chemokines for recruiting bone marrow-derived immune cells. However, non-
hematopoietic cells cannot migrate to draining LNs to prime naïve T cells and probably 
mediate in local memory responses. Skeletal muscle cells, which are especially exposed to 
intramuscular vaccines and bone marrow-derived non-classical APCs like neutrophils, do not 
constitutively express MHC II required for CD4+ T cell dependent adaptive responses. 
However, MHC II expression can be induced in skeletal muscle (44) during inflammatory 
conditions and neutrophils (45) express both MHC II and T cell co-stimulatory molecules 
under these conditions. The expression of MHC I expression for CD8+ T cell responses is 
detectable on neutrophils and nearly absent in normal skeletal muscle but can be upregulated 
in presence of cytokines (46-48).  In addition, TLR4 is expressed by human neutrophils (49) 
and TLR7 can be detected on skeletal muscle of patients with inflammatory muscle disorders 
(50), which suggest that these cells have the necessary PRRs to respond to licensed adjuvants 
targeting these TLRs. Moreover, mouse neutrophils have reported to be able to capture 
antigens in the periphery and shuttle vaccine antigens to LNs and express chemokine 
receptors for homing to LNs (51, 52).  Interestingly, human neutrophils in spleen have 
reported to support antibody responses via cytokines (53) and mouse neutrophils seem 
capable of inducing T cell responses to protein antigen (54). Although these reports suggest 
that neutrophils positively support adaptive responses, the opposite effect has also been 
observed in mice (55). In general mouse and human neutrophils differ in expression of 
several markers involved in both innate and adaptive immunity (56). For example, mouse and 
not human neutrophils produce the immunosuppressive cytokine IL-10 (57) and the co-
stimulatory molecule B7-H3 activate T cells in humans but inhibits T cell activation in mice 
(56, 58). The proportions of neutrophils and lymphocytes are also different between mice and 
humans (56). However, human neutrophils have also been shown to suppress CD4+ T cell 
responses, while supporting B cell responses (53). Thus, the role of neutrophils in vaccine-
induced adaptive responses needs further elucidation.  
 
1.4.3 Human dendritic cells in blood  
Human DCs comprise multiple subsets with distinct functions and represents approximately 
0.5 % of peripheral blood leukocytes (59). In general, human blood DCs can be divided into 
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two major subsets: myeloid DCs (MDCs) and plasmacytoid DCs (PDCs). While PDCs are 
normally absent in skin, MDCs are found residing in normal skin. However, the MDCs in 
both blood and skin are further subdivided into several subsets (Fig. 3). The existence of 
multiple DC subsets with distinct functions suggest a division of labor regarding the 
stimulation and regulation of adaptive immune responses (39). In humans, PDCs express the 
interleukin (IL) -3 receptor (CD123), CD303 (BDCA-2) and CD304 (BDCA-4) (60, 61). 
PDCs are especially competent in antiviral immunity due to their capacity to rapidly produce 
high amounts of type I IFNs in response to viruses, which can also activate other APCs in a 
bystander manner (62). However, they may also play role in tolerance in mucosal tissue (63). 
PDCs sense viral nucleic acids via TLR7 and TLR9, and respond readily to synthetic agonists 
to these receptors (64), which indicate their susceptibility to activation by adjuvants targeting 
these TLRs. Interestingly, reports have also suggested that DAMPS such as host cell-derived 
self-nucleic acids can activate PDCs (65, 66). Type I IFNs have also been shown to support 
antibody responses in humans (67, 68) and mice (69). In addition, PDCs have also been 
reported to support Th1 responses in presence viral antigens (70, 71). Thus, an adjuvant that 
targets e.g. TLR7 could lead to strong PDC activation and bystander activation of other cells, 
which subsequently could support both humoral and cell-mediated immunity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While two subsets of PDCs in human blood have been reported (72), circulating MDCs are 
subdivided into distinct subsets defined by their respective expression of CD1c (BDCA-1)+ 
MDCs, CD141 (BDCA-3)+ MDCs and CD16 (61, 73). PDCs, CD1c+ MDCs and CD141+ 
MDCs are also found residing in lymphoid tissues (74) where antigen presentation occurs. 
All DC subsets are capable of presenting antigens, although the MDC subsets and in 
particular CD1c+ MDCs, have shown to be more efficient in stimulating CD4+ T cell 
responses compared to PDCs (75-78). CD1c+ MDCs express TLR4, TLR7 and TLR8 (73, 75) 
Figure 3. The phenotype of human DC subsets in skin and blood.  
LC (Langerhans cells), DDC (Dermal DCs, MDC (Myeloid DC), PDC (Plasmacytoid DC)  
 
SKIN 
BLOOD 
PDCs 
CD123+ 
CD303 (BDCA-2)+ 
CD304 (BDCA-4)+ 
 
CD141+ MDC 
CD141 (BDCA-3)+ 
DNGR-1/Clec9a+ 
CD11c + 
 CD16+ MDC 
CD16 + 
CD11c + 
 CD1C+ MDC 
CD1c (BDCA-1) + 
CD11c+ 
 
LCs 
CD207 (Langerin)+ 
CD1a+ 
 
DDCs 
CD209 (DC-SIGN)+/– 
CD207 (langerin)+/– 
CD1a+/– 
CD14+/– 
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and when they infiltrate vaccine delivery sites, TLR-targeting adjuvants may activate them to 
induce specific adaptive immune responses. For example, activated MDCs can produce IL-
12, which supports cell-mediated responses by inducing CTL response. Cross-presentation 
enables extracellular antigens to be presented on MHC I (for CD8+ T cell responses) instead 
of MHC II (for CD4+ T cell responses). CD141+ MDCs have been reported to be superior in 
cross-presentation (61, 79, 80), which may induce CTLs to control of intracellular infections. 
However, the contribution of antigen presentation by CD141+ MDCs may be small since they 
comprise only 0.04% of PBMCs and recently human CD1c+ MDCs as well as PDCs have 
shown to cross-present antigens as well (81, 82). In contrast, the CD16+ MDCs are the most 
abundant DC subset in the blood and have lower capacity to present antigens compared to 
other MDC subsets (73, 75). The CD16+ MDCs have been suggested to have a more 
inflammatory phenotype due to their rapid production of pro-inflammatory cytokines such as 
TNF-α. Compared to other MDCs, TLR4 is highly expressed by CD16+ MDCs (73, 75), and 
they might contribute to the adjuvant effect of MPL in licensed vaccines. 
 
1.4.4 Human dendritic cells in skin 
While MDCs and PDCs are found in blood and lymphoid tissues, only DCs of the myeloid 
origin are found in the skin during normal conditions, which make these MDCs readily 
available target cells for intradermal vaccines or skin test antigens. The human skin is divided 
into the outermost layer called epidermis, which faces the external environment, and the 
underlying dermis. While the epidermis is cell dense, the dermis consists mainly of collagen 
matrix with scattered cell populations such as macrophages and DCs. Skin-residing DCs are 
broadly defined as epidermal Langerhans cells (LCs) and dermal DCs (DDCs) (83). The LCs 
were the first identified skin-DC subset by Langerhans in 1868 but Steinman and Cohn first 
demonstrated their function in 1973. LCs highly express langerin (CD207), CD1a and 
Birbeck granules, which are unique in LCs (83). However, langerin expression has also been 
observed in some DDCs, but it is unclear if they represent epidermal LCs migrating to 
draining LNs or a distinct DDC subset. The DDCs are heterogeneous and their definition 
varies due to lack of specific markers. Nevertheless, DDCs can be divided into two major 
subsets; DC-SIGN+ (CD209), CD14+, CD1alow and langerin– DDCs and DC-SIGN–, CD14–, 
CD1a+, langerin– DDCs (83) and referred to as CD14+ DDCs and CD1a+ DDCs. Regarding 
TLR expression, CD14+ DDCs and LCs seem to express TLR4, which suggest that they 
might respond to TLR4 agonist adjuvanted vaccines delivered to the skin (84, 85). Live 
attenuated BCG vaccine and yellow fever vaccine are safe for administration to dermis and 
subcutis respectively. These vaccines do not contain adjuvants but they have intrinsic PAMPs 
themselves that likely target TLRs. Whether subunit protein vaccines formulated with TLR 
agonists can be delivered to the human skin needs to be further addressed.  
 
1.4.5 Phenotypic maturation of dendritic cells  
The quality of vaccine-induced immunity may depend on how an adjuvant influences DC 
activation, which involves upregulation of proteins necessary for antigen presentation, T cell 
stimulation and migration to lymphoid tissues. The functional properties of DCs depend on 
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whether they are in a resting or activated state, which is referred to as “immature” and 
“mature” respectively. DC maturation involves morphological and functional changes 
subsequent to activation via e.g. TLRs (5, 86). In normal conditions, DCs in peripheral tissues 
are described “immature” with an exceptional capacity to take up antigens and express 
relatively low levels of MHC II, T cell co-stimulatory molecules e.g. CD80, CD86, CD40 
(86). Upon activation, mature DCs reduce their antigen uptake capacity and instead 
upregulate MHC and co-stimulatory molecules as well as the chemokine receptor, CCR7 for 
migration to draining LNs. The amount of T helper cells and their qualitative properties are 
likely dependent on antigen presentation in secondary lymphoid organs, where rare antigen-
specific naïve T cells interact with mature DCs.  
 
1.4.6 Shaping of T cell immunity by dendritic cells  
Generally, three types of stimuli are involved to prime T cells leading to proliferation (i.e. 
clonal expansion) and differentiation (15, 87, 88). The first stimulus involves engagement of 
MHC-peptide complex and TCR. Simultaneously, T cells receive the second stimulus when 
co-stimulatory molecule on DCs, e.g. CD80 binds to CD28 on T cells. The third stimulus 
consists of cytokines, where IL-12 (IL-12p70) and IL-10 derived from DCs induce 
differentiation of Th1 and Th2 effector cells respectively with distinct cytokine profiles. 
While Th1 effector cells secrete primarily IL-2 and IFN-γ, Th2 effectors secrete IL-4, IL-5, 
IL-10 and IL-13 (20) and the type of Th effector cells determine the outcome of infections. 
For example, at the site of pathogenic insult, Th1 effector cell secrete IFN-γ to enhance 
clearance of infected cells by macrophages and release of IL-5 by Th2 effector cells facilitate 
killing of parasitic worms. Priming of CD8+ T cells leads to expansion and differentiation 
into CTLs secreting e.g. IFN-γ, TNF-α, and IL-2 plus the cytolytic effector molecules; 
granzyme A/B and perforin. As mentioned above, cross-presentation by CD141+ MDCs plus 
IL-12 derived from CD1c+ MDCs has been reported to induce antigen-specific CD8+ T cells 
responses (79, 89). The CD40-CD40L interaction between CD4+ T cells and DCs is also 
believed to help DCs induce CD8+ T cell responses (21, 90) and this interaction may enable 
protein-based vaccines to induce CTLs. However, DC and T cell interaction could also lead 
to tolerogenic responses (63, 87), which may contribute to the tolerability aspect of adjuvants. 
Regarding skin-DCs, epidermal LCs were found to be more efficient in inducing CTLs 
compared to CD14+ DDCs in mouse studies (84). LCs were also better than CD14+ DDCs at 
cross-presentation and generated CTLs displaying higher TCR avidity and more abundant 
cytotoxic effector molecules (84).  
 
1.4.7 Antibody responses mediated by dendritic cells 
Since most vaccines typically induce antibody responses (91), understanding the events that 
determine the quality and quantity of antibodies is highly relevant in vaccinology. One of the 
goals for preventive vaccines is to elicit neutralizing antibodies that can block infection by 
binding to epitopes on pathogen molecules to hinder successful infection. Therefore, 
neutralizing antibodies with broad specificity are needed for pathogens that frequently alter 
their epitopes by mutation (92). The quality of an antibody can also be defined by its affinity 
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i.e. the strength it binds to the epitope, which increases the probability for the antibody to 
remain bound to its epitope and sustain neutralization. Generating neutralizing antibodies 
with high affinity requires affinity maturation associated with somatic hypermutation (SHM), 
where gene segments affecting the variable regions are recombined to generate mutated 
antibodies with augmented functions (93, 94). More often, antibodies bind antigens in order 
to make them susceptible for phagocytosis. Gene recombination is also involved in switching 
of the invariant part of the antibody called Fc-region. The Fc-region determines the isotype 
(or class) of the antibody and enables interaction with cells through isotype-specific Fc-
receptors during e.g. uptake of antibody-coated antigens. Thus, how efficient vaccine-induced 
antibodies perform these functions may reflect on the capacity of the vaccine to provide 
protection. Several events such as isotype-switch, SHM and generation of long-lived plasma 
cells secreting high affinity antibodies occur in the germinal centers (GCs) where Tfh cells 
provide of T cell help to antigen-specific B cells (19, 95, 96).  
 
In regards to DCs supporting GC reactions, human CD14+ DDCs but not LCs or CD1a+ 
DDCs have been shown to polarize naïve CD4+ T cells to Tfh-like cells (97). In contrast, LCs 
seem better than CD14+ DDCs in inducing naive CD4+ T cells into Th2 effector cells that 
secrete IL-4, IL-5 and IL-13, which are known to support antibody responses (97). Further, 
IL-12 produced by human monocyte derived DCs (MoDCs) has been shown to induce Tfh-
like cells that secrete IL-21 for regulation of antibody responses in vitro (98). Both T cell 
dependent and independent B cell responses leading to isotype switch are also supported by 
PDCs (68) and the DC- and neutrophil-derived cytokine, B cell-activating factor (BAFF) 
promote B cell survival and plasma cell differentiation (68, 99, 100). To this end, antibody 
responses induced by protein-based vaccines are likely dependent on T cell help and TLR7 
and TLR9 expressed by PDCs and B cells may enhance these responses. In addition, mouse 
studies have reported that DCs can facilitate antibody responses by providing antigens to B 
cells (101).  
 
1.4.8 T follicular helper cells and germinal center reaction  
In general, antibody production is T cell independent or dependent. Responses to proteins 
typically requires CD4+ T cell help (102). While naïve B cells can acquire large particulate 
antigens attached on macrophages, follicular dendritic cells (FDCs) or DCs, small antigens 
might directly pass into the B cell zone from afferent lymph vessels (103). After encountering 
protein antigens, B cells migrate to the T cell-B cell border to receive T cell help. Antigen 
presentation and co-stimulation between the antigen-specific lymphocytes lead to a short B 
cell proliferation and the B cell progenies then differentiate along two pathways (96). While 
the follicular pathway give rise to germinal centers (GCs), the extrafollicular pathway result 
short-lived plasma cells. In the follicular pathway, some of the expanded progenies migrate to 
B cell zone to proliferate intensely and thereby give rise to the so-called dark zone of the GC. 
Proliferating B cells in the dark zone are called centroblasts, which undergo SHM and 
isotype-switch. Subsequently, centroblasts exit the cell cycle to become centrocytes and 
acquire antigen supplied by FDCs, which they present to Tfh cells in the so-called light zone. 
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Interaction with Tfh result in; a) survival and selection of high-affinity centrocytes, b) 
recycling of centrocytes back to the dark zone for another round of SHM and isotype-switch, 
or c) differentiation into long-lived plasma cells and memory B cells. The positively selected 
B cells with high affinity BCR leave the GC either as plasmablast (precursor to the antibody 
secreting plasma cells) or as memory B cells, which rapidly differentiate into plasma cells 
upon antigen re-exposure (104). The GC reaction may therefore correlate with the quality of 
vaccine-induced humoral response since it gives rise to long-lived plasma cells secreting 
antibodies with improved functionality (94). Therefore, adjuvants that induce appropriate 
stimulation of APCs at the site of administration may reflect on the subsequent Tfh cell 
differentiation and GC formations (Fig. 4). 
 
1.4.9 Establishment and stimulation of memory responses 
Upon re-encounter with the same pathogen, the immunological memory enables quicker and 
more robust responses. As mentioned, this concept represents the basis for vaccination. In 
fact, repetitive immunization (i.e. boosting) is needed for many vaccines to maintain antigen 
specific immunity at protective levels. Protection is mediated by antibodies secreted by long-
lived plasma cells residing in the bone marrow in an antigen-independent manner to maintain 
constant antibody levels in blood and body fluids (105). During antigen re-encounter, 
memory B cells proliferate rapidly and differentiate to plasma cells, which can be indicated 
by transient elevation of antibodies in the blood (16). In the cellular immune system, tissue-
resident memory T cells are able to provide immediate effector function upon antigen re-
exposure. Instead, recall responses are mediated by central memory T cells in T cell areas of 
secondary lymphoid organs where they quickly proliferate after antigen presentation by DCs 
(16).  
 
1.4.10 Skin antigen tests for cell-mediated immunological memory 
While local memory responses in skeletal muscle remain elusive, one of the earliest 
characterized memory responses is the delayed type hypersensitivity (DTH) reaction in skin. 
Figure 4. General view on the immune events occurring from vaccine administration to the generation 
of adaptive immunity. 
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In the clinic, measuring DTH responses enable assessment of the ability to mount cell-
mediated memory responses to various antigens including antigens derived from mumps 
virus or Candida albicans commensal yeast or purified protein derivate (PPD) from 
Mycobacterium tuberculosis (MTB). The skin tests are frequently used on immune-
compromised individuals to evaluate the integrity of their cell-mediated immunity. These 
skin antigen tests are normally delivered intradermally. The most common skin test is using 
PPD as antigen for evaluation of pre-existing immunity to MTB or its vaccine (BCG). This 
test is called Mantoux test or tuberculin skin test (TST). At 48-72 hrs after injection with 
PPD, the inflammatory DTH reaction causes an induration (rigid protruding swelling) at the 
injection site that can be visualized and palpated (106, 107). The diameter of the induration 
represents the estimate for the TST and considered positive at ≥10 mm according to WHO 
standards, and sometimes at ≥ 5 mm where tuberculosis exposure are low. The DTH reaction 
is likely initiated by DCs taking up the skin test antigens and presenting them to skin-residing 
memory T cells, which then secrete cytokines that activate DCs or other cells locally in a 
direct or bystander manner. Mature DCs then migrate to draining LNs in order to present 
antigens to antigen-specific memory T cells, which respond by proliferation and home to the 
antigen injection site to maintain inflammatory responses such as recruitment of immune 
cells until the antigen is cleared (106).   
 
1.5 VACCINES AGAINST HUMAN IMMUNODEFICIENCY VIRUS  
1.5.1 Human immunodeficiency virus  
HIV is an enveloped RNA virus that belongs to the retrovirus family and that causes acquired 
immunodeficiency syndrome (AIDS) (108). Like other retroviruses HIV carries the viral 
enzyme reverse transcriptase, which transcribes its RNA to DNA that can be incorporated to 
the host genome and cause chronic infection. Two types of HIV infect humans. While HIV-2 
is less transmissible, cause slower disease progression and mainly prevalent in the Africa, the 
more virulent HIV-1 is the predominant type spreading throughout the world (109). HIV-1 is 
divided into three major groups (M, N & O) and group M, which can be further subdivided 
several clades (i.e. subtypes), is responsible for the majority of HIV-1 infections worldwide. 
While clade B is most prevalent in the Americas and Western Europe, clade C is the major 
subtype in e.g. South Africa (110). HIV-1 infects its main target cell, the CD4+ T cells, by 
binding to the CD4 receptor and chemokine receptor CXCR4 or CCR5. However, HIV-1 can 
also infect other cells such as DCs (111-113), although the main hallmark of HIV disease is 
the severe depletion of CD4+ T cells. According to WHO staging systems, AIDS diagnosis 
usually follows CD4 T cell counts that are less than 200 /µL blood. AIDS patients are 
susceptible to several opportunistic infections including invasive Candida infection, 
Pneumocystis carinii pneumonia, and Kaposi sarcoma, which usually cause AIDS-related 
deaths. Highly active anti-retroviral therapy (HAART) is generally efficient at controlling the 
viral load and thereby prevents the decline of CD4+ T cells and progression to AIDS.  
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1.5.2 Dendritic cells and HIV-infection 
The numbers of both MDCs and PDCs are declined in blood early in the infection (114, 115). 
However, while some MDC subsets are replenished after HAART, recovery of PDCs seems 
less efficient (116, 117) and treated patients show lower levels of both DC subsets compared 
to uninfected individuals (116). The mechanism behind depletion of blood DCs is unknown 
although pro-apoptotic markers are increased in MDCs of HIV-1+ individuals (118) and 
infection, although very low, of both DC subsets has also been reported (119). However, DCs 
have also shown to mobilize to lymphoid tissues (120-122), which may cause the decline of 
DCs in blood. Whether DC functions remain intact in HIV patients are not clear. Both MDCs 
and PDCs from HIV-1-infected patients showed impaired antigen presentation capacity in 
vitro (119). In addition, influenza and herpes simplex viruses stimulated lower type I IFN 
levels in PBMCs (116) and isolated PDCs (123) from HIV-1+ individuals, but can be restored 
after HAART (123). However, there are also reports showing MDCs and PDCs in HIV-1+ 
individuals more readily secrete cytokines compared to healthy subjects and may thereby 
contribute to the chronic immune activation during HIV-1 infection (124, 125). Although 
these results seem contradictory, they imply that DC functions likely are affected during 
HIV-1 infection.  
1.5.3 HIV vaccines 
According to WHO, almost 37 million people live with HIV worldwide and 2 million HIV-
related deaths have been reported during 2014. When HIV was established as the cause of 
AIDS in the early 1980’s, there was great optimism that preventive HIV vaccines could be 
developed relatively quickly (126). After 30 years of intense HIV research, there is still no 
protective vaccine. Multiple HIV vaccine approaches have been developed, but as mentioned 
below only few have advanced to human efficacy trials (126, 127).  
 
Since current vaccines mostly protect via antibodies, the first HIV-1 vaccine clinical trials 
(VaxGen) tested recombinant envelope protein of HIV (Env, gp120) administrated together 
with alum as the adjuvant. The vaccine induced strain-specific gp120 antibodies but they did 
not prevent infection of field strains of HIV-1 in high-risk populations. Subsequent trials 
(STEP) explored a recombinant adenovirus type 5-based vaccine encoding different HIV-1 
proteins aimed to stimulate cell-mediated immunity. This trial was halted before completion 
due to lack of prevention of HIV-1 infection. In 2009, the RV144 trial used a vaccination 
strategy comprised of canarypox viral vaccine vector followed by Env gp120 in alum boost, 
which provided a 31.2% efficacy. Lastly, an efficacy trial was launched the same year 
(HVTN 505), using DNA vaccine encoding HIV-1 proteins from clades A, B and C followed 
by adenoviral vector encoding e.g. Env from the same clades. Unfortunately, this latest 
efficacy trial also failed to prevent HIV-1 infection or reduce virus levels and was stopped 
two years later (126).  
 
There are clearly significant challenges in HIV-1 vaccine development. Although no clear 
correlation between protection and neutralizing antibodies was found in the RV144 trial, this 
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so far most successful efficacy trial resulted in an optimistic view of the effect of non-
neutralizing antibodies which in combination with innate cells such as NK cells may 
contribute to protective responses (126, 128). Given that Env is the only viral protein 
expressed on HIV’s surface, understanding its detailed structure is likely critical for inducing 
HIV-1-specific antibodies, including those able to neutralize. In fact, one of the major 
obstacles in HIV-1 vaccine development is constructing structurally optimal Env that can 
induce broadly neutralizing antibodies (128). There is still no proven consensus whether 
antibody or T cell responses are the most feasible type of immunity that can be simulated by a 
vaccine to prevent and/or control HIV-1 infection. Vaccines that induce both cell-mediated 
and humoral immunity may be most efficient. Nevertheless, HIV-1 protein antigens that are 
structurally accurate would need adjuvants to elicit sufficiently potent and durable vaccine 
responses. Understanding how such responses can be induced i.e. the influence of innate cells 
such as DCs, capture, present HIV-1 antigens, stimulate adaptive responses and how 
adjuvants affect these processes is receiving increasing attention (128).  
 
After the modest success of the RV144 HIV-1 vaccine trial where alum-adjuvanted HIV-1 
Env was used as a boost, MF59 has been suggested to replace alum in future clinical trials to 
increase efficacy using this vaccine regimen (129). MF59 has been shown to be a potent and 
safe adjuvant for HIV candidate vaccine trials in humans (130) and NHPs (131). In fact, this 
prompted some of the studies in this thesis where the effect of MF59 versus alum was 
investigated in terms of their capacity to generate immune responses to HIV-1 Env.  
 
 
1.6 NONHUMAN PRIMATE MODELS FOR VACCINE RESPONSES 
Nonhuman primates (NHPs) play a crucial role for modeling vaccine responses in humans, 
including new vaccines designed for malaria and HIV-1 (132). Although inbred rodent strains 
are frequently used and suitable for addressing specific research questions, they differ 
substantially in their distribution of immune cell populations, phenotype and PRRs compared 
to humans (56). In contrast, humans and rhesus macaques share high degree of similarities as 
shown by the comparable distribution of lymphocyte and APC populations, which can be 
identified using same phenotypic markers (Fig. 5) (64, 133-137). In adjuvant research where 
TLR agonists provide means to target specific immune cells rhesus macaques provide a 
powerful model since their DCs express similar sets of TLRs as humans, which is in contrast 
to mice (137, 138). Rhesus DCs also respond to TLR stimulation by upregulating maturation 
markers and produce cytokines in a similar manner (64, 138, 139). Thus, the similar 
expression and functionality of TLRs on both rhesus macaque and human DCs indicate that 
rhesus macaques model in vivo adjuvant responses more accurately compared to rodents 
(137). The memory lymphocyte pool in rhesus macaques, including Tfh cells and plasma 
cells, has also been characterized (136, 137, 140, 141), which enables both enumeration and 
functional analysis of these effector cells before and after vaccination. Importantly, antigen 
doses used in rodents may not be proportionally representative for clinical use (10, 33). 
Moreover, as in human vaccination, most antigens in NHP studies are delivered in the muscle 
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instead of the intraperitoneal route commonly used in mouse studies. Intradermal delivery of 
adjuvant alone (142) or together with antigen (143, 144) in rhesus macaques has also been 
employed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rhesus macaques are frequently used as in vivo models to evaluate efficacy of candidate 
vaccines against HIV-1 (145, 146). Although rhesus macaques more rapidly progress to 
AIDS, the signs of disease progression in terms of viral load and CD4+ T cell counts are 
similar in SIV and HIV-1 infection (145, 147-149). The depletion of blood DC subsets in 
humans is mirrored in SIV+ rhesus macaques (150). Numerous vaccine immunogenicity 
studies using NHPs report potency and efficacy by measuring antibody levels and/or T cell 
responses in blood. However, the immune events initiated locally at the immunization site 
and those giving rise to measurable adaptive immune responses week(s) later remain elusive. 
Based on the above, rhesus macaques represent an excellent in vivo model for studying local 
immune responses at the site of vaccine delivery as well as initiation of adaptive immunity. 
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Figure 5. Flow cytometric identification of human and rhesus DC subsets in PBMCs with antibodies 
against human markers. DCs are lineage–, HLA-DR+, CD14 –. Myeloid DCs are CD11c+ and 
plasmacytoid DCs are CD123+.  
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2 AIMS OF THIS THESIS 
The overall aim of this thesis was to investigate the early innate immune responses in vivo 
after administration of antigens. We addressed this both during recall of immunological 
memory responses locally (clinical skin tests) as well as priming of naïve responses in the 
presence of different adjuvants (vaccination). The specific aims for the individual studies are: 
 
Paper I: To study the recruitment and function of human dendritic cell subsets in 
tuberculin skin tests. 
 
Paper II:  To compare recruitment of dendritic cells and T cells in response to skin 
antigen tests in healthy versus HIV-1 infected individuals.  
 
Paper III:  To establish a nonhuman primate in vivo model to study early local innate 
immune responses at the site of intramuscular immunization. 
 
Paper IV: To model how distinct adjuvants induce innate stimulation to enhance vaccine 
responses in nonhuman primates.  
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3 MATERIALS AND METHODS 
The methods used in the papers for the thesis papers are briefly outlined below. For more 
detailed description, see “materials and methods” of each paper. The bold roman numerals 
indicate the paper(s), where the specific method or treatment was applied. 
3.1 ANTIGEN DELIVERY   
3.1.1 Skin test antigens 
The volunteers in studies of local immune responses after intradermal delivery of skin test 
antigens were recruited in Cape Town, South Africa (I-II) or Cleveland, USA (II). The South 
African cohort is from an area with frequent exposure to MTB (151). Thus, subjects with 
previous tuberculosis diagnosis and/or symptoms were excluded. Intradermal injection of 
PPD (I-II) was done according to international standards and TST reaction ≥10 mm was 
considered positive. Same subjects also received intradermal saline-injection on the other arm 
as control. The Cleveland cohort received antigens from C. albicans and mumps virus (II), 
but considered positive at ≥5 mm and non-injected skin served as control. 
3.1.2 Antigens for intramuscular injections 
Antigens modeling vaccines for studies of intramuscular immunization (IV) consisted of 
HIV-1 Env gp120 monomer derived from the Tv1 or SF162 strains. Env was fluorescently 
labeled with AlexaFluor 680 (Molecular Probes) and administrated alone or mixed 1:1 with 
oil-in-water adjuvant MF59 labeled with DiO. Alternatively, labeled Env was adsorbed to 
aluminum hydroxide adjuvant (alum) or to alum pre-adsorbed with a TLR7 agonist. Animals 
were generally injected with Env alone or Env together with one of the adjuvants at two 
different sites. The third and fourth site respectively was injected with PBS and adjuvant 
alone. In a separate group of animals, each site received Env plus adjuvant at a different time 
point. To model immune responses to viral vector vaccine (III), replication-incompetent 
recombinant adenovirus serotype 5 (rAd5) encoding Ebola glycoprotein was used. During 
general anesthesia, animals were placed in recovery position and injections were 
administered in a 90° angle at the midpoint of the encircled injection site. 
3.2 COLLECTION OF BIOPSIES FOR IN SITU ANALYSIS 
For the in situ studies of human skin, local anesthetic was administered prior collection of 
punch biopsies from non-injected skin (II) and skin intradermally injected with skin test 
antigen or saline (I-II) at 48 hrs post-injection as described (152). For the studies of rhesus 
macaque skeletal muscle (III-IV), biopsies were collected during necropsy. Animals were 
placed in same position as during immunization and a biopsy punch was pressed through 
skin, adipose and connective tissue at the center of the encircled skin area (i.e. needle entry 
point) to create a puncture mark on the underlying muscle. The muscle tissue surrounding this 
puncture mark indicated antigen-exposed muscle from which the punch biopsies were 
collected. LNs draining the injected muscles were also harvested. All biopsies were snap-
frozen in liquid nitrogen. 
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3.3 TISSUE STAINING AND IN SITU ANALYSIS 
3.3.1 Immunohistochemistry  
To analyze and quantify DC subsets and markers of inflammation in situ at the intradermal 
delivery site of skin test antigens or saline (I-II) as well as non-injected skin (II), fixed 
sections of snap-frozen human skin biopsies were permeabilized with saponin (Sigma). 
Unspecific staining due to endogenous peroxidase, avidin and biotin, were blocked with 
hydrogen peroxide and avidin-biotin blocking kit (Vector). Incubation with primary 
antibodies was done overnight. Non-specific binding of the secondary antibodies was blocked 
with sera (Dako) from the species the secondary Abs were derived from. Sections were 
incubated with biotinylated secondary antibodies (Dako) and staining was visualized by 
Vectastain Elite ABC kit (Vector) containing streptavidin-conjugated peroxidase followed by 
3,3’-diaminobenzidine (DAB) peroxidase substrate kit (Vector). Cell nuclei were 
counterstained with haematoxylin. All incubations were done at RT. The DAB staining was 
analyzed with bright field light microscope coupled to computerized image analysis system 
as previously described (153). Quantification of skin sections was performed in the dermis 
except for Langerin, which was done in the epidermis only. Melanin-rich cells between 
epidermis and dermis were excluded from the analysis. 
3.3.2 Immunofluorescent staining 
For in situ analysis of human skin (II-III) and rhesus muscle and draining LNs (IV), 
cryosections were stained as above, but visualized by streptavidin-conjugated fluorophores 
(Molecular Probes). To investigate the distribution of labeled antigen and adjuvant in the 
muscle (IV), sections were incubated with wheat germ agglutinin to visualize muscle fiber 
bundles. All incubations were done at RT and in dark. Sections were mounted with SlowFade 
Gold antifade regent (Molecular Probes) with or without DAPI for nuclear counterstaining. 
Imaging and analysis was done with confocal microscopy. 
3.3.3 Analysis of germinal centers  
To assess the number and size of germinal centers in LNs (IV), tiled images of entire LN 
sections were acquired. The GC formations in B cell areas were defined via Ki67+ CD3– cells 
(proliferating B cells in the dark zone) and PD-1+ CD3+ cells (Tfh cells in the light zone). 
Ki67+ PD-1+ cells in T cell areas were excluded since these are most likely activated T cells. 
Enumeration of GCs and measurement of GC area plus the whole LN section were performed 
in a blinded fashion on tiled images using Fiji software.  
3.4 PREPARATION OF SINGLE CELL SUSPENSION OF SOLID TISSUES  
3.4.1 Skeletal muscle tissue 
Multiparametric flow cytometry was used to simultaneously enumerate and phenotype the 
infiltrating immune cells after intramuscular antigen delivery (III-IV), as well as assess their 
activation status and antigen uptake capacity in vivo (IV). A cubical piece of approximately 
15 cm3 was dissected from the antigen injection site. Each dissected muscle tissue was 
weighed and normalized to 4 g by removal of adipose and connective tissues as well as 
excess muscle tissue. Muscle were then cut into small pieces and digested with RPMI 
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containing Liberase (Roche), which is a collagenase mixture, and DNase (Sigma) without 
agitation for 2 hrs at +37C°. Liberase activity was inactivated by RPMI supplemented with 
FCS. Inactivated digestion was filtered through 70 µm cell strainers (BD), washed and single 
cell suspension was resuspended to approximately 1 g tissue/ml.  
3.4.2 Processing of lymph nodes 
For flow cytometric evaluation of immune cell accumulation in LNs draining injected muscle 
and presence of labeled antigens and adjuvants (IV), LNs were cut into smaller pieces, passed 
through 70 µm cell strainer with a plunger, washed and resuspended to 5 x106 cells/ml. 
3.5 FLOW CYTOMETRY  
Multiparameter flow cytometric analysis was applied to both human (I) and rhesus macaques 
(III-IV) samples. Cells were washed with PBS, incubated with Aqua dye (Molecular Probes) 
for live/dead staining and blocked with FcR-blocking reagent (Miltenyi) before adding a 
cocktail of fluorescently labeled monoclonal antibodies. Cells were washed after incubation, 
fixed and on average 2 x106 events per sample were acquired using an LSR II flow cytometer 
(BD). Analysis was done with FlowJo software (Tree Star). Number of cells was obtained by 
normalizing to 1 x 105 viable cells (% Aqua dim/– cell subset divided by102 and then multiplied 
with 105). In some samples, a known number of AccuCount beads (Spherotech) were added 
to samples before acquisition and numbers of cell subsets were calculated (cell subset count / 
bead count) x (bead number / sample volume), as described (154). 
3.6 ISOLATION OF ANTIGEN PRESENTING CELLS 
3.6.1 Isolation of primary dendritic cells for in vitro assays  
DCs were isolated from buffy coats, aphaeresed blood and elutriated monocytes for in vitro 
stimulations (I). Enrichment of DCs was done prior to DC isolation. RosetteSep monocyte 
enrichment cocktail (Stemcell Technologies) was added to buffy coat to deplete lymphocytes, 
granulocytes and erythrocytes during ficoll separation. MDCs and PDCs were magnetically 
isolated using anti-CD1c and anti-CD304 (BDCA-4) microbeads (Miltenyi) and AutoMACS 
(Miltenyi).  
3.6.2 Isolation of immune cells for ex vivo antigen presentation assay 
To compare antigen presentation capacity of Env+ APCs in the draining LNs from rhesus 
macaques, flow cytometry sorting was applied to ensure high cell purity (IV). Cell 
suspensions of LNs draining muscle injected with AlexaFluor 680-labeled Env plus adjuvant 
or PBS, 24 hr earlier, were stained to identify CD14+ monocytes, CD11c+ MDCs and CD66 
abce+ neutrophils. Using FACSAria (BD), Env+ cells were sorted and placed in co-cultures 
with sorted autologous CD4+ T cells from stored PBMC samples from peak Env-specific 
immunity. 
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3.7 FUNCTIONAL ASSAYS 
3.7.1 Antigen uptake by human primary dendritic cells in vitro  
Uptake of PPD (Statens Serum Institut) (I) was assessed by labeling it with AlexaFluor 488 
(Molecular Probes) and adding it to enriched APCs or isolated MDCs and PDCs for 2 hrs at 
+37C° or +4C°. PPD-uptake was analyzed by flow cytometry or confocal microscopy. 
3.7.2 In vitro stimulation of human primary dendritic cells 
For DC activation in vitro (I), magnetically isolated PDCs were stimulated with either PPD, 
LL37 (Innovagen), CpG ODN (class B 10103, Coley), human DNA (Biochain) or LL37 
complexed with DNA or CpG ODN for 16 h at +37°C. In some experiments, supernatants of 
stimulated PDC were added to MDCs to assess bystander stimulation, PPD uptake and 
proliferation of CD4+ T cells. For in vitro stimulation with adjuvants, flow cytometer sorted 
monocytes, MDCs, PDCs and neutrophils were incubated with MF59, alum or alum-TLR7 
overnight. While expression of co-stimulatory molecules CD80, CD86 and CD40 was 
assessed by flow cytometry, cytokine secretion was measured by ELISA (PBL) or Luminex 
assay (Invitrogen) according to the manufacturers instructions.  
3.7.3 Ex vivo antigen presentation assay 
For comparison of antigen presentation capacity, Env+ APCs isolated from rhesus LNs and 
autologous CD4+ T cells as described above (IV) were co-cultured for 5 days and responding 
Env-specific CD4+ T cells were analyzed via CFSE dilution using flow cytometry. To 
investigate the presence of Env-specific CD4+ T cell responses in LNs after prime or boost 
(IV), LNs draining vaccination sites were collected at different time points as indicated and 
processed into cell suspensions. The suspensions were CFSE-labeled and cultured for 5 days 
in absence or presence of either Env protein (HIV-1 Tv1 strain) or Env peptides. CD4+ T 
cells were gated during FlowJo analysis to measure Env-specific responses by CFSE dilution. 
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4 RESULTS AND DISCUSSION 
This thesis has evolved around the early innate immune responses such as immune cell 
recruitment and local immune activation after administration of antigen and onset of immune 
responses in vivo. The studies were performed by first studying the local immune responses 
after clinical skin tests in humans (paper I-II) and second by studying vaccine administration 
in a rhesus macaque model (paper III-IV).  
4.1 INFLAMMATORY RESPONSES AFTER SKIN ANTIGEN TEST DELIVERY 
In paper I-II we utilized human skin punch biopsies sampled after clinical skin tests. This 
was a valuable material to assess innate immune activation in vivo 48 hrs after antigen 
delivery in humans. As described in section 1.4.10, the DTH reaction induced by pre-existing 
immunity to skin test antigens including PPD used for TST, evaluates the presence and 
integrity of cell-mediated memory responses. Positive DTH reaction indicated by the 
induration is caused by inflammation, which may be initiated only a few hours after the skin 
test antigen delivery due to detectable erythema (155, 156). Neutrophils and monocytes are 
known to arrive first to inflammatory sites (157-159). In line with this, the majority of 
infiltrating cells during very early time points (4–6 hrs) in TST reaction have been shown to 
be CD11b+ cells, which represent neutrophils and monocytes (155). T cells are detected 
around 12 hrs later (156). HLA-DR+ APCs have also been shown to accumulate in this 
reaction (156, 160, 161). Since DTH reactions are based on reactivation of memory 
responses, they unlikely model the events occurring during primary intradermal vaccinations. 
In addition, the antigen mixes used for the skin tests do not contain immune stimulatory 
substances unlike unadjuvanted clinical intradermal vaccines against e.g. influenza, BCG or 
rabies, which contain intrinsic PAMPs. In paper I, the inertness of PPD was demonstrated by 
the lack of immune cell recruitment or activation in negative TST reactions found in 
individuals with no pre-existing immunity. In contrast, local immune activation in the 
positive indurations appears as a consequence of inflammation and cytokines such as IFN-
γ  secreted from recruited antigen-specific memory T cells in the TST reaction (106, 161, 
162). Indeed, IFN-γ was detected in our skin biopsies material from the TST site in a previous 
study (152). Inflammatory cytokines such as IFN-γ, TNF-α and IL-1β have been reported in 
human skin biopsies already at 6-24 hrs after PPD-injection, which is considerably ahead of 
the peak DTH response occurring at 48-72 hrs (161, 162). Intradermal delivery of 
recombinant IFN-γ into the skin of healthy volunteers was shown to induce local 
inflammatory responses such as upregulation of chemokine genes and promote influx of 
immune cells (163).  
 
4.1.1 Dendritic cells are recruited to the site of skin antigen test injection 
In paper I, we performed an in situ characterization and quantification of multiple DC 
subsets in the skin of healthy donors receiving intradermal injection of PPD and saline on 
separate sites. Inflammation was detected by the robust immune cell infiltration in the 
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positive TST induration as indicated by the increased cellularity in the dermis. There was a 
higher percentage of HLA-DR+ cells in the TST reaction compared to the saline-injected 
control skin. As shown in paper II, the presence of DC infiltration was accompanied by 
significantly higher levels of CD3+ T cells in the positive TST reaction as compared to TST 
negative test sites. This suggests that there is a recruitment of DCs following PPD-injection 
as long as there is concurrent infiltration of pre-existing antigen-specific memory T cells to 
the site. Several markers defining CD123+, CD303+ PDCs and subsets of MDCs such as 
Langerin, DC-SIGN, CD11c, CD68 and CD141 were used to identify the infiltrating DC 
subsets. Both total CD11c+ DCs and CD123+ PDCs were significantly increased in the TST 
site compared to control skin (Fig. 6). Although HLA-DR+ APCs in positive TST indurations 
have been previously shown (156, 160), the definition of DC subsets has not been reported. 
Our in situ analysis therefore showed for the first time that both PDCs and CD141+ MDCs, 
which are otherwise rare cells in skin (164), infiltrate TST indurations.  
 
 
 
 
 
 
 
 
 
 
 
 
As described above in section 1.4.3, CD141+ MDCs have been reported to be superior in 
cross-presentation and PDCs excel in mounting anti-viral responses by secreting high levels 
of type I IFNs. Infiltration of CD141+ MDCs plus IFN-α secreted by PDCs at the site of 
antigen delivery may influence the type of T cell response stimulated. Whether CD141+ 
MDCs can enhance CD8+ T cell responses or impact the DTH responses remains elusive 
while the role of PDCs is discussed below. 
4.1.2 Immune activation of plasmacytoid dendritic cells in positive TST indurations  
Since the finding that PDCs accumulated in positive skin indurations was intriguing, we 
further analyzed whether they were activated and contributed to inflammation. Since PDCs 
are efficient producers of type I IFNs such as IFN-α, we stained for the MxA protein, which 
is exclusively upregulated by cells exposed to type I or III IFNs (165). We found significant 
increase of MxA in the TST reactions compared to control skin. This is indicative of PDC 
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activation in the positive indurations. Although other cells also can produce type I IFNs and 
cause MxA expression, PDCs are able to rapidly secrete type IFNs at levels that are several 
magnitudes higher (166). IFN-α producing PDCs have been detected in autoimmune skin 
disorders like lupus and psoriasis (66, 166, 167). The shared feature of DTH reactions and 
autoimmune skin disorders is that immune activation is induced in the absence of microbial 
stimuli. We therefore explored the potential cause for the induction of type I IFNs in the 
positive TST induration. We confirmed that the PPD antigen was unable to directly activate 
PDCs in vitro, nor induce PDC infiltration in individuals with negative induration. In general, 
inflammation causes varying degrees of cell death induced by different pathways (168) and 
presence of self-nucleic acids derived from dead cells are a plausible source for PDC 
activation. In fact, neutrophils, which are commonly found in inflammatory tissues, have 
been proposed to release self-DNA that activates PDCs during lupus erythematous (169, 
170). To this end, we also found that neutrophils were present in the positive indurations (F. 
Liang, unpublished data). Strictly intracellular antigens like self-nucleic acids in the 
extracellular environment act as danger signals and are referred to as DAMPs, which also 
include the anti-microbial peptide LL37. Complexes of self-nucleic acids and LL37 have 
been demonstrated to activate PDCs in psoriasis lesions and the complex formation rescued 
self-nucleic acids from extracellular degradation (65, 66). Indeed, we found increased 
staining of LL37 as well as markers associated with cell death (caspase-3) or lost cell 
integrity (HMGB-1 and lactate dehydrogenase) in the PPD-injected skin. We were not able to 
detect extracellular nucleic acids, which may relate to insufficient detection limit. However, 
the presence of extracellular staining of HMGB-1 protein that interacts with DNA in the cell 
nuclei, partially suggests that self-nucleic acids may be found outside the cell. This 
demonstrates that there are stimulatory complexes present in the TST induration that can 
activate PDCs. The data suggest that antigen injection sites with substantial inflammation 
including cell death facilitate DC recruitment and this milieu also contains stimulatory 
components that activate DCs and can induce a type I IFN response.  
4.1.3 Dendritic cell recruitment to skin is compromised during HIV-1 infection 
As mentioned in section 1.5.2, CD4+ T cells and blood DCs are depleted during HIV-1 
infection. Whether fundamental DC functions such as mobilization to antigen delivery sites 
and antigen presentation are intact in HIV-1 patients is not clear. In paper II, we studied if 
the robust DC infiltration to positive skin test indurations also was detected in HIV-1 patients. 
We compared the magnitude of DC infiltration in TST indurations of healthy, asymptomatic 
HIV-1+ individuals and AIDS patients. As shown in paper I, accumulation of DCs in the 
positive TST induration. In paper II we also expanded the analyses to include other skin 
antigen tests to see whether DTH indurations in general would induce the same level of DC 
recruitment. We quantified DCs in skin indurations of healthy and HIV-1+ individuals after 
injection with skin test antigens derived from mumps virus and the gut commensal yeast C. 
albicans. Immunity to these antigens is established by mumps vaccination and constant 
exposure to C. albicans respectively. In contrast to the well-established depletion of blood 
DCs during HIV-1 infection, we did not find reduced levels of DCs in skin biopsies from 
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HIV-1+ individuals. The saline-injected control skin of healthy and HIV-1+ individuals had 
similar levels of staining representing MDCs (CD11c+ total MDCs including CD141+ MDCs) 
and CD123+, CD303+ PDCs (Fig. 7). Frequencies of MDC subsets and PDCs were higher in 
the positive indurations compared to the control skin in all donors, regardless of whether they 
were healthy or HIV-1+. However, the accumulation of the MDC subsets and CD303+ PDCs 
were significantly lower in the HIV-1+ individuals and especially in those with AIDS. In fact, 
the level of DC infiltration correlated with the magnitude of CD3+ T cell infiltration in the 
positive TST indurations. 
 
 
 
 
 
 
 
As described above for the TST indurations, both healthy and HIV-1+ individuals had higher 
recruitment of MDCs and PDCs in indurations caused by mumps and C. albicans antigens 
compared to control skin from the same donors. However, there was a differential pattern of 
DC recruitment depending on the type of skin test antigen and HIV-1 seropositivity. When 
comparing the level of DC accumulation in the indurations of HIV-1+ and healthy 
individuals, we observed that C. albicans antigens induced a higher level of DC influx than 
mumps antigens in asymptomatic HIV-1+ individuals. In contrast, mumps induced higher DC 
levels than C. albicans in the healthy subjects. In these study groups, the differential pattern 
of DC levels was related to the levels of T cell infiltration. The level of memory T cells 
specific for the respective antigens likely determine the level of DC recruitment. In this 
regard, high levels of CD45RO+ cells (memory T cell marker) were found in healthy 
individuals after mumps-injection and in line with this, CD45RO+ cells were especially 
elevated after C. albicans-injection in asymptomatic HIV-1+ individuals. This could explain 
the more efficient C. albicans-specific T cell responses observed in HIV-1+ individuals 
compared to healthy controls (171, 172). Thus, the level of T cell accumulation, which likely 
contains pre-existing antigen-specific memory T cells, influences the level of inflammation 
that in turn dictates the level of DC recruitment.  
Figure 7. Compiled data on the frequencies of total CD11c+ MDCs, CD123+ or CD303+ PDCs and the 
cross-presenting CD141+ MDC subset in healthy versus HIV-1+ individuals, including AIDS patients.  
Saline (–), positive TST (P) and negative TST (P*). (Figures from paper II) 
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4.2 NONHUMAN PRIMATE MODEL FOR EARLY VACCINE RESPONSES 
Increased knowledge of the innate immune mechanisms involved in initiating and regulating 
adaptive immunity after antigen administration is important for understanding how vaccine 
responses are elicited and can be manipulated for better efficacy. The observations of rapid 
and robust recruitment of several DC subsets to the site of skin test antigen administration as 
well as local inflammation in paper I-II, encouraged subsequent studies to determine how 
vaccine injection influences these processes. In the second part of my thesis, I therefore took 
another approach and in paper III-IV we established an animal model predictive of humans 
to be able to sample and comprehensively study innate immune stimulation over time 
following intramuscular injection of a protein vaccine antigen together with distinctly 
different adjuvants.    
 
In the first part of my thesis, we studied the innate immune responses during recall of 
memory responses and the injected antigens in these studies were also different compared to 
those used in subsequent studies. The skin test antigens used in humans (paper I- II) 
stimulate pre-existing immunity and are not designed to prime immunity. In contrast, the 
antigens in (paper III-IV) i.e. adenoviral vaccine vector encoding Ebola glycoprotein (paper 
III) and the candidate vaccine antigen HIV-1 Env (paper IV) are designed to prime immune 
memory in antigen-naïve animals. Despite these fundamental differences, the distinct 
antigens may share some common features.  First, they all have the capacity to promote local 
inflammatory responses either directly via adjuvants (paper IV) or intrinsic adenoviral 
PAMPs (paper III) or indirectly via pre-existing memory cells (paper I-II). Second, they all 
require antigen presentation to stimulate T cell responses. Thus, recruitment of immune cells 
to the site of antigen injection in either system likely precedes migration and antigen 
presentation in draining LNs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Schema of intramuscular antigen injection and tissue sampling. Injection area was encircled 
on shaved skin (solid circle) and antigen was administered at the midpoint. A biopsy punch pressed 
through the skin at the center of encircled area created a mark on the underlying muscle tissue and 
indicated the injection area (dotted circle, upper far right). Muscle tissue proximal to this mark (within 
the dashed square) was collected. (Figure from paper III)  
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As described in section 1.6, NHPs offer a powerful in vivo model for generating data on 
vaccine responses that may be translatable to humans. Although rhesus macaques are 
frequent in vivo models for vaccine studies, the end point of these studies are usually derived 
from analysis of post-challenge protection and/or adaptive responses in sera or PBMCs. The 
innate immune events such as recruitment of immune cells to the muscle, where most clinical 
vaccines are delivered, remain elusive. Performing comprehensive studies of immune cell 
infiltration and activation after vaccine administration in human muscle are challenged by the 
invasiveness of muscle biopsy collecting and the fact that muscle tissue contains relatively 
few immune cells (41), which, means that rather sizeable biopsies are required for 
reproducible data. 
 
In paper III, we developed protocols for precise collection and dissociation of NHP muscle 
biopsies to be able to address questions related to the early local immune responses after 
vaccination. To mobilize immune cells, intramuscular injection with an adenoviral vaccine 
vector was performed 72 hrs prior to tissue sampling during necropsy. In paper III, much 
attention was focused on finding procedures for exact sampling of the tissue that was in 
closest proximity to the vaccine injection (Fig 8). These procedures are described in section 
3.1.2 and 3.4.1. An overview of injection and tissue sampling is depicted above. The 
protocols developed in paper III, enabled detailed characterization of the innate immune 
cells present in rhesus macaque muscle after intramuscular injection with model vaccines. 
We found that the number of live immune cells per gram muscle that could be retrieved was 
around 7 x105. More than ten different immune cell subsets were identifiable using antibodies 
for classical human CD-markers. These cell subsets include; CD66abce+ neutrophils, CD14+ 
CD11b+ monocytes, CD14+ CD11b – macrophages, CD123+ PDCs, CD1c+ MDCs, CD16+ 
MDCs, CD4+ T cells, CD8+ T cells, CD20+ B cells, CD16+ and CD16 – NK cells. PBMCs 
from the same animals were also stained as controls and all subsets, except macrophages 
were detected (F. Liang, unpublished data). Immune cells in blood, lymphoid and mucosal 
tissue of rhesus macaques have been characterized to various extents (64, 135, 140, 173, 
174). However, infiltrating immune cells in immunized muscle has mainly been studied in 
mice (35, 42). The protocol refinement and validation of the detection of rhesus immune cells 
in paper III were important for proceeding to subsequent studies of innate stimulation after 
vaccination performed in paper IV.  
 
4.3 INNATE IMMUNE RESPONSES INDUCED BY DISTINCT ADJUVANTS 
Capitalizing on the experience and method development from the earlier papers in the thesis, 
we were able to in perform an extensive project characterizing how early innate stimulation 
by different adjuvants shape vaccine responses in paper IV. In this study, we examined 
intramuscular injections of fluorescently labeled HIV-1 Env, co-delivered with distinct 
adjuvants, already approved for human use or on a clinical path. We investigated MF59 (oil-
in water emulsion), alum (benchmark adjuvant) and a TLR7-agoinst adsorbed to alum (alum-
TLR7). MF59 and alum-TLR7 were chosen since they are distinctly different in their 
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composition and they both have recently proven to induce superior vaccine responses over 
alum (175). The NHP model allowed us to simultaneously phenotype multiple immune cells 
in the muscle and draining LNs, assess vaccine-induced activation of specific cell subsets, 
track the distribution of labeled vaccine antigens and identify when and where adaptive T and 
B cell responses were formed. The animals were divided in four different groups receiving 
Env alone or together with either MF59, alum or alum-TLR7. We started by comparing the 
local immune responses in the vaccine-injected muscle to control muscles from the same 
animal that were injected with PBS and only adjuvant respectively. 
4.3.1 Dendritic cells, neutrophils and monocytes infiltrated all adjuvant-injected muscles 
As DCs are essential for priming of naïve T cell responses their recruitment is considered to 
be critical for priming of vaccine responses. We found that CD11c+ MDCs and CD123+ 
PDCs were significantly increased in adjuvant-injected muscle compared to PBS-injected 
muscle of the same animals. Both MF59 and alum-TLR7 induced higher recruitment of 
MDCs to the muscle compared to alum and PDCs were highest in alum-TLR7 group (Fig 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The majority of the MDCs comprised of the CD1c–, CD16– population, which may indicate 
that infiltrating monocytes may also have differentiated to DCs as shown in mice (176). No 
or very few tissue resident CD103+ DCs, or skin-resident CD1a+ LCs or DC-SIGN+ DDCs 
were detected in the muscle, which suggests that the DCs infiltrating vaccine-injected 
muscles came from the blood rather than from adjacent tissues. Regarding the CD141+ 
MDCs, no optimal cross-reactive CD141 antibody exists. By using alternative markers 
expressed on human CD141+ MDCs, this rare subset has recently been identifiable in rhesus 
macaques (177) although we did not have the reagents available at the time of our study.  
Figure 9. Rapid and transient immune cell infiltration and uptake of fluorescently labeled Env by indicated 
cells over time. (Figure from paper IV). 
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Apart from DCs, we found a large infiltration of CD66abce+ neutrophils and CD14+ 
monocytes in muscles injected adjuvants (Fig 9). As previously discussed, monocytes and 
neutrophils are known to be the first cell types to arrive tissue exposed to inflammatory 
stimuli (159). Previous mouse studies have found that infiltrating monocytes and neutrophils 
were the predominant cell populations infiltrating the muscle after MF59 and alum injection 
(42). . In line with this we found that monocytes and neutrophils were the dominant cell types 
at the site injected with either of the adjuvants. The infiltration of DCs, monocytes and 
neutrophils into the muscle was detected already at 2 hrs and peaked at 24 hrs. Interestingly, 
this is usually the time soreness appears in the muscle after being vaccinated.   
 
4.3.2 Mobilization of cells to draining lymph nodes 
A large infiltration of DCs, monocytes and neutrophils to the muscle after vaccination 
followed by sustained migration to draining LNs may be advantageous for generation of 
strong adaptive responses. The accumulation of these cells in the LNs draining the injected 
muscle followed similar kinetics as the infiltration into the muscle and peaked at 24 hrs. In 
line with these findings, expression of CCR2, mediating transmigration of immune cells from 
the circulation to tissues, was most pronounced on these cells at 24 hrs. Similarly, CCR7, 
mediating migration to LNs, was highest at 24 hrs. While MDCs expressing higher levels of 
CCR2 and CCR7 were found in the MF59 group, PDCs expressing highest level of these 
chemokine receptors were found in the alum-TLR7 group, which may contribute to the 
respective DC recruitment patterns induced by these adjuvants. In the MF59 and alum-TLR7 
groups, DCs were still elevated at 72 hrs and had not completely returned to baseline levels 
after 10 days. This suggests that the inflammation created by MF59 and alum-TLR7 at the 
injection site may be more persistent than with alum, which resulted prolonged cell 
infiltration.  
 
The PDCs and CD1c+ MDCs were proportionally more frequent in the draining LNs 
compared to the CD16+ MDCs, which were very few in the draining LNs. This indicates that 
specific DC subsets have distinct migration pattern and also may reflect their distinct 
functions during early vaccine responses. As mentioned in section 1.4.3, CD1c+ MDCs are 
especially efficient in stimulating CD4+ T cell responses while CD16+ MDCs have been 
described as pro-inflammatory. Thus, CD16+ MDCs may be most useful for promoting an 
inflammatory milieu in the muscle to recruit and activate CD1c+ MDCs in the muscle, which 
then migrate to LNs in order to present antigen to CD4+ T cell responses.  
 
Monocytes are frequently used for in vitro differentiation of DCs (MoDCs) and known for 
their ability to home to tissues and differentiate to macrophages or DCs (178). Monocytes 
stimulated in vitro with MF59 have been shown to differentiate to DCs reminiscent of 
moDCs and upregulated chemokine receptor CCR7, involved in migration to LNs (179). 
Mouse studies have shown that neutrophils can upregulate CCR7 and migrate to draining 
LNs (52) where antigen presentation occurs. In this regard, we found highest CCR7 
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upregulation on neutrophils and monocytes in the animals receiving MF59 injection, which 
suggests efficient LN homing of these cells in the MF59 group. We found that MF59 
exclusively induced neutrophils to migrate to draining LNs. Mouse studies showed that 
neutrophils can upregulate MHC II and co-stimulatory molecules and present protein 
antigens to CD4+ T cells (54, 180). Neutrophils have also been proposed to support B cell 
responses by secreting cytokines that promote B cell survival and differentiation (53).  
 
4.4 FUNCTIONALITY OF IMMUNE CELLS IN MUSCLE AND LYMPH NODES 
4.4.1 Adjuvants induce distinct innate activation profiles 
The efficiency to induce DC activation directly or indirectly is likely an important property of 
an adjuvant (30, 181). We found that MF59 and alum occasionally induced upregulation of 
co-stimulatory molecules on infiltrating MDCs, PDCs, monocytes and neutrophils in the 
adjuvant-injected muscle compared to the donor-matched PBS-injected muscles. In contrast, 
alum-TLR7 consistently induced upregulation of co-stimulatory molecule in all animals and 
at all time points (2-72 hrs). TLR7 stimulation has previously been shown to induce strong 
activation of especially PDCs (64, 142, 182). We found that MDCs, monocytes and 
neutrophils were also able to phenotypically differentiate directly or indirectly by alum-
TLR7.  
 
Since PDCs express high levels of TLR7 and respond with abundant production of type IFNs, 
we analyzed MxA expression in the muscle and draining LNs of adjuvant- and PBS-injected 
muscle. As mentioned earlier, MxA is expressed only in cells responding to type I IFNs. We 
found MxA+ cells only in the alum-TLR7- injected muscles and its draining LNs. A recent 
study in mice receiving intramuscular injection with TLR7 agonist (adsorbed to alum), 
resulted upregulation of multiple genes associated with type I IFNs in the injected muscle 
(37). However, MxA expression was absent in the injected muscle and draining LNs in alum 
or MF59 groups. Although alum-TLR7 was more efficient in inducing phenotypic maturation 
and type I IFNs, the other adjuvants and especially MF59, was also able to induce local 
cytokine response. In fact, we found that infiltrating APCs produced IL-8 and MCP-1 
especially after administration of MF59 and alum-TLR7.  
 
We found that neutrophils, which are not perceived as classical APCs, were able to 
upregulate HLA-DR (MHC II) in response to either adjuvant. However, the stimulated 
neutrophils expressed much lower levels of HLA-DR compared to the levels found expressed 
by MDCs and monocytes with or without adjuvant exposure. The reason why MF59 in 
particular induced neutrophil accumulation in LNs needs further investigation. It has been 
shown that MF59 adjuvanticity is likely independent of TLR signaling, as previously 
suggested for alum (183). Previous rabbit studies indicate that MF59 creates an “immune 
competent milieu” since MF59 delivered a day before antigen delivery at the same site still 
enabled induction of immunity, while the opposite order of delivery did not. This suggests 
that MF59 creates an environment that is beneficial to mount antigen-specific immune 
responses once the subsequent antigen is delivered. It was demonstrated in mice that potent 
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vaccine responses were induced when MF59 and antigen were co-delivered to the same site, 
but not when these components were delivered to separate sites (33). Other mouse studies 
showed that MF59 induces upregulation of genes involved in immune activation with higher 
magnitude compared to alum and many of these genes encoded cytokines, chemokines, 
cytokine receptors, proteins necessary for migration, and antigen presentation associated 
genes (35). The gene expression data confirmed that an immunocompetent environment was 
created at the MF59 injection site, which was also supported by the robust influx of e.g. 
monocytes, neutrophils and DCs, as well as cytokine production (35, 42). The cells initiating 
the immunocompetent environment may be resident macrophages and muscle cells that are 
activated by MF59 and this milieu promotes recruitment of immune cells.  
4.4.2 Antigen uptake in muscle and draining lymph nodes 
The generation of antigen-specific adaptive immunity requires internalization of antigens, 
processing to peptides for presentation via MHC molecules. Therefore, efficient delivery of 
vaccine antigen to cells is likely needed for induction of strong vaccine immunity. 
Fluorescent labeling of Env with AlexaFluor 680 enabled assessment of in vivo Env uptake 
and distribution in our studies. Since Env was adsorbed to alum and alum-TLR7, both 
vaccine protein antigen and adjuvant were tracked simultaneously. MF59 was labeled with 
lipophilic dye DiO and could therefore be separately detected when co-administered with the 
labeled Env.  
 
In line with the cell infiltration kinetics, Env+ as well as MF59+ cells including, neutrophils, 
monocytes and DCs were the highest at 24 hrs in the muscle (Fig 9.). Since there were 
numerous infiltrating neutrophils and monocytes after injection with any of the adjuvants, a 
large proportion of the Env+ cells were also represented by these cells. We selected the 
AlexaFluor-dye for labeling Env since it is stable and can be detected inside cells for a longer 
period. Importantly, the AlexaFluor-signal indicates Env uptake at some point but it does not 
mean that the Env protein is still intact. Low levels of MF59 were still detectable at day 10 
and both MF59 and alum-TLR7 group had also low numbers of DCs at this time point. This 
is likely due to sustained low grade inflammation induced by these adjuvants during earlier 
time points rather than a depot effect. On this regard, one of the proposed mechanisms for 
alum is that it causes antigen retention at the delivery site, which allows extended antigen 
availability for sustained antigen uptake and stimulation (26). However, this concept has been 
challenged by independent studies showing efficient antigen clearance from the vaccination 
site as well as unchanged immune memory when tissue receiving the vaccine was surgically 
removed after immunization (26, 27). Increased antigen uptake by APCs has also been shown 
when antigens were adsorbed to alum (26) and this may lead to improved antigen processing 
and presentation.  
 
Env+ and/or MF59+ cells were exclusively detected in the LNs that drained the muscles 
injected with vaccines and were not found in LNs draining PBS-injected muscle, which is in 
line with earlier mouse studies (42, 184). The Env+ cells in the draining LNs are likely a 
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mixture of cells that acquired Env at the injection site or at the draining LN since injected 
antigens may also passively reach the LNs. The proportions of different types of Env+ cells in 
the draining LNs were different compared to those detected in the muscle. A larger 
proportion of Env+ MDCs and Env+ PDCs were found in the alum and alum-TLR7 groups 
compared to the MF59 group where Env+ cells were mainly monocytes and neutrophils.   
4.4.3 Antigen presentation capacity of Env+ cells in draining lymph nodes   
Since we detected considerable numbers of Env+ monocytes and neutrophils in the draining 
LNs, we compared their capacity to present Env to autologous CD4+ T cells side-by-side with 
MDCs. To enable this comparison in our NHP model, we utilized a set of animals that were 
previously immunized with Env and adjuvant (about 2 years earlier) and had PBMCs stored 
from the time they had well-detectable Env-specific CD4+ T cell responses. In this study, the 
same animals received an injection with fluorescently labeled Env together with either of the 
adjuvants and PBS was injected in the opposite arm. At 24 hrs, the draining LNs were 
collected for isolation of highly purified Env+ MDCs, monocytes and neutrophils by flow 
cytometry. From LNs draining PBS injection, we isolated the same cell subsets, which were 
Env –. The cells were then co-cultured with CD4+ T cells isolated from the stored PBMCs. 
Proliferation of Env-specific CD4+ T cells, as a result of antigen presentation, was assessed 
by CFSE dilution.  
 
 
 
 
 
 
 
As expected, MDCs were found to be most efficient at presenting Env and inducing 
proliferation of responding Env-specific CD4+ T cells (Fig 10). Proliferating T cells were also 
detected in co-cultures with monocytes. However, neutrophils were also able to present Env 
to a lower degree. As mentioned above, neutrophils in mice have been shown to present 
antigens to T cells (54, 180). However, other mouse studies suggested that antigen uptake by 
mouse neutrophils interfered with T cell responses by making antigens less available for DCs 
to present (55). Nevertheless, we found that the hierarchy of Env presentation capacity of 
MDCs, monocytes and neutrophils remained the same regardless of the adjuvant used. 
 
Figure 10. CFSE dilution of autologous CD4+ T cells for measuring antigen presentation capacity of different 
Env+ APCs found in LN draining muscle injected Env plus adjuvant. The Env – APCs were isolated from LN 
draining PBS-injected muscle in the same animals.  (Figure from paper IV). 
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Although neutrophils are considered to be rather short-lived cells, they have been reported to 
survive for five days (185) and T cells have also been shown to support neutrophil survival in 
co-cultures (186). Therefore, it is likely that some of the neutrophils in our co-culture system 
remained viable. By using highly purified human neutrophils, monocytes and DCs isolated 
from donors with chronic cytomegalovirus (CMV) infection, we confirmed that neutrophils 
were able to stimulate autologous CD4+ T cell cytokine production after 24 hrs co-culture in 
presence of pp65 CMV protein (F. Liang, unpublished data). However, the T cell 
proliferation represents memory T cell responses and neutrophils may not have the capacity 
to prime T cell responses since their levels of HLA-DR and co-stimulatory molecules are not 
as high as on DCs. Nevertheless, this suggests that the mobilized neutrophils in the draining 
LNs, especially in the MF59 group, can present Env to already primed memory T cells during 
boost. The abundance of neutrophils in the immune system may also compensate for their 
lesser efficiency to present antigens.  
 
4.5 GENERATION OF PRIMARY ENV-SPECIFIC IMMUNITY  
4.5.1 Initiation of primary Env-specific CD4+ T cells  
Further, in paper IV we analyzed whether the kinetics and magnitude of primary Env-
specific CD4+ T cell responses were different between the adjuvants. We immunized Env 
naïve animals at different sites and different time points and collected the draining LNs to 
evaluate Env-specific CD4+ T cell responses. The LN cells were CFSE-labeled, re-stimulated 
in vitro with Env protein or peptides and cultured for five days.  
 
We found no Env-specific CD4+ T cells in LNs draining muscle that was immunized 2 hrs or 
24 hrs before LN collection. Low but detectable levels of responding T cells were found at 72 
hrs post-injection, but the Env-specific responses were most pronounced in LNs draining 
muscle immunized 10 days earlier (Fig. 11). The responses were antigen-specific since there 
was no proliferation in absence of Env. Interestingly, LNs that did not drain any of the 
immunization sites, such as mesenteric LNs lacked responding CD4+ T cells at day 10. This 
suggests that the generation of responses occurs primarily in the LNs draining the vaccine 
administration site and that dissemination of Env-specific T cells to other LNs are not 
detectable level during the first 10 days of priming. Animals receiving either MF59 or alum-
TLR7 showed higher proliferation compared to the animals in the alum group (Fig. 11). This 
could relate to the higher mobilization and activation of APCs observed in MF59 and alum-
TLR7, which in turn suggest that more efficient antigen presentation was induced by these 
adjuvants.  
 
To measure whether Env-specific T cells are disseminated to non-draining LNs after boosts, 
we analyzed responses in LNs draining muscles receiving the fifth immunization with Env 
and adjuvants 10 days earlier. We observed again that Env-specific T cells were 
predominantly found in LNs draining the muscle injected with Env and adjuvant. However, 
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low amounts of CD4+ T cell responses were found in LNs draining PBS injection, which 
suggests that Env-specific T cells are disseminated to other LNs after boost vaccination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5.2 Accumulation of T follicular helper cells  
The quality of the antibodies has been reported to correlate with levels of Tfh cells (187, 
188), which are essential for generation of GC reaction that give rise to neutralizing 
antibodies and long-lived plasma cells. Tfh cells highly express Bcl6 (transcription factor), 
CXCR5 (chemokine receptor for homing to the B cell follicles and germinal centers) and PD-
1 (receptor involved in attenuation of immune responses) (19, 96). Lack of Tfh cells in mice 
is associated with both the absence of GCs and durable antibody responses (189). Since we 
detected Env-specific T cell responses 10 days after prime, we estimated the levels of Tfh in 
the same draining LNs. The Tfh cells were identified as CD3+ CD4+ T cells with high 
expression of CXCR5 and PD-1 among the central memory T cells (CD28high and CD95high) 
as described earlier (136, 187) (Fig. 12). We found significantly higher numbers of Tfh cells 
in draining LNs of muscles that received MF59 and alum-TLR7 compared to alum (Fig 12). 
Figure 11. Presentation of Env protein or peptides in LNs draining muscle injected with Env plus indicated 
adjuvant at different time points. (Figure from paper IV). 
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This is supported by recent mouse studies that also showed that MF59 induced higher Tfh 
numbers 10 days after prime compared to alum (190, 191).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As mentioned earlier, neutrophils have been shown to support B cell responses by secretion 
of BAFF, APRIL and IL-21 (53). It has also been reported that IL-21 support Tfh 
differentiation (192). MF59 also induced homing of monocytes to the draining LNs and 
activated monocytes are able to upregulate the ICOS-ligand (193, 194), which is essential for 
differentiation of Tfh cells (192, 195-197). Therefore, the preferential mobilization of 
neutrophils and monocytes to draining LNs induced by MF59 may support the differentiation 
of Tfh cells. Further, influenza hemagglutinin (HA) with MF59 induced higher levels of both 
Tfh cells and GC B cells compared to unadjuvanted HA in adult and infant mice (191). As 
mentioned earlier, the adjuvant effect of MF59 has been proposed to be independent of TLRs 
(183). In contrast, the TLR7 agonist adsorbed to alum in our studies activates through TLR7 
(37). Since the highest levels of PDCs and MxA expression were found in LNs draining 
muscle injected with alum-TLR7, it is likely that type I IFNs play a role in the adjuvanticity 
of alum-TLR7. Indeed, IFN-α supports both B cell and T cell responses (69, 198). In 
addition, DCs including PDCs are capable of producing IL-6 (67), which is also important for 
Tfh differentiation (189, 195). In this regard, mice that received intramuscular injections of 
the same TLR7 agonist used in our studies induced significantly higher IL-6 serum levels 
compared to alum (37). We also found that MF59 or alum-TLR7, but not alum, resulted in 
elevated serum IL-6 levels, and that only alum-TLR7 induced IL-6 secretion by highly 
purified MDCs, PDCs and neutrophils in vitro (F. Liang, unpublished data). Since B cells are 
also APCs expressing TLR7, they may also contribute to Tfh differentiation. In line with 
previous studies (42), Env+ B cells were most frequent in the draining LNs at 24 hrs in all 
adjuvant groups. This suggests that B cells, like DCs, can take up Env, become activated by 
the adjuvants and stimulate the differentiation of Tfh cells via CD40 and ICOS-ligand co-
stimulation during antigen presentation. However, the APC population that is most influential 
Figure 12. . Gating strategy of Tfh cells in LN at day 10 and compiled data on Tfh cells frequencies in the 
indicated adjuvant groups. (Figure from paper IV).  
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for Tfh differentiation is still unclear. Studies in mice with CD4+ T cells incapable of having 
sustained contact-dependent interaction with B cells, but interacts as normal with DCs, could 
still express Bcl6, CXCR5 and migrate to B cell follicles like Tfh cells (189). This was also 
observed in mice where HLA-DR was expressed by DCs and not by B cells (199). 
Nevertheless, differentiation of Tfh cells and their long-term maintenance are diminished in 
the absence of B cells (189) or when B cells do not express MHC II (199), which is likely due 
to loss of co-stimulation from B cells. It has also been suggested that DCs prime naïve T cells 
into Tfh cells and antigen presentation by B cells are important once Tfh are located in B cell 
areas (200). Thus, multiple APCs are likely needed for the complete differentiation of Tfh 
cells and more investigations are needed to elucidate the mechanisms by which alum-TLR7 
and MF59 support these events. 
 
4.5.3 Formation of germinal centers  
Tfh cells are essential for the GC reaction (95) and the number of Tfh cells correlated with 
the frequencies of GC B cells in immunized mice (191, 197). Importantly, our collaborators 
recently reported that NHPs immunized Env with MF59 or alum-TLR7 induced significantly 
higher HIV-1 specific neutralizing antibodies compared to those given Env alone or together 
with alum (175). They also found higher levels of Env-specific memory B cells and IgG 
titers. This clearly demonstrates that different adjuvants have different potency. In this regard, 
the more pronounced innate activation induced by MF59 and alum-TLR7 in our study likely 
play a key role behind their findings. Our observation of higher levels of Tfh cells after prime 
in the MF59 and alum-TLR7 groups, prompted us to evaluate whether the number and size of 
GCs were affected. To define GCs structures, we stained for PD-1+ Tfh cells and Ki67+ 
proliferating GC B cells in cryosections of LNs draining muscle injected with Env and 
adjuvant 10 days earlier (Fig. 13). These markers readily defined GCs both in human and 
rhesus macaque tonsil and LNs (136, 201, 202). The clusters of Ki67+ and PD-1+ cells were 
located opposite to each other, which indicated the dark and light zone of the GCs 
respectively, and were found mainly in the B cell areas. We found the highest number of GCs 
in the MF59 group followed by the alum-TLR7 group (Fig. 13). Similarly, MF59 was shown 
to induce higher GC numbers in mice at 10 days (190, 191) and at one month after prime 
(190). We also found that the frequencies of Ki67+ cells in the B cell areas significantly 
correlated with the size of the GCs (F. Liang unpublished data), which is in line with previous 
reports (202, 203). It is possible that the rapid turn over of proliferating Ki67+ B cells, 
increases the size of the GGs. In fact, higher GC numbers and larger GC area have been 
reported to correlate with amounts of antigen-specific IgG titers in immunized mice (204) as 
well as controlling SIV disease (202). To this end, we found that as with GC numbers, the 
area of individual GCs, with or without normalizing for entire LN section area, were larger in 
MF59 and alum-TLR7 group compared to the alum group (Fig. 13).  
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As mentioned, proliferating Ki67+ B cells correlated with size of GGs. In fact, the GC B cell 
is the most rapidly dividing mammalian cell type (104). B cells express TLR7 and have been 
shown to proliferate efficiently after TLR7 stimulation (64, 205), which was further enhanced 
by IFN-α (64). This suggests that alum-TLR7 may influence the proliferation of GC B cells. 
Our in situ analysis showed that Env+ cells were found in non-B cell areas at 24 hrs after 
immunization but no longer detectable at the 10 days time point. However, Env+ B cells were 
detected at 24 hrs and they have likely acquired antigen in the T cell areas, including the T 
cell-B cell border. Thus, alum-TLR7 presumably supports transient proliferation of antigen-
specific naïve B cells at the T cell-B cell border rather than GC B cells in B cell areas. 
However, the contribution of direct activation of B cells via TLRs in vaccine responses is 
controversial. In mice where only the B cells lack MyD88 (an essential protein for conveying 
activation via most TLRs, including TLR7 and TLR9) had unchanged antigen-specific IgG 
titers compared to wildtype mice after immunization with protein antigen adjuvanted by 
TLR9 agonist (206). In the same study, deficiency of MyD88 only in DCs resulted in 
significantly reduced IgG titers. This suggests that B cell mediated responses to protein-based 
vaccines are likely due to bystander activation rather than direct B cell activation via TLRs 
(205). This would mean that the strong DC activation and type I IFN responses in LNs 
draining alum-TLR7-injected muscle are important for B cell responses. However, other 
mouse studies have also shown that TLR activation in B cells is essential (205) and B cell 
responses by the extrafollicular pathway (GC independent) are enhanced by TLR activation 
in B cells (205, 206). TLR activation of human B cells in vitro has also been reported to 
support isotype-switching (207). Nevertheless, the durability of GCs may also lead to 
qualitatively better antibody responses since SHM and isotype-switch may occur for an 
extended time. The kinetics of GC has primarily been studied in mice and the GC numbers 
peak around day 10 after immunization and remains consistent for up to 3 weeks, while the 
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Figure 13. GC formations as defined by staining of CD3, 
Ki67 and PD-1 in the 10 days LNs of the indicated adjuvant 
groups. Compiled data show number of GCs and area with 
or without normalization with the tissue section area. 
(Figure from paper IV). 
  40 
GC area gradually decreased (203). Whether the GC numbers and size in NHPs are altered 
beyond 10 days after prime need further investigations. Since adjuvants have shown to 
increase both GC numbers (190, 204, 208) and size in mice (204), they may also influence 
the durability of GC formations. Persistent antigen availability has been shown to play a role 
in the maintenance of Tfh cells within GCs (197), which in turn may sustain the number and 
size of GCs. In a previous mouse study, MF59-adjuvanted proteins were found retained in 
GCs as immune complexes (antibody-antigen aggregates) for up to 7 days after boost (209). 
We did not detect extracellular or cell-associated Env in draining LNs at day 10 after prime 
but it is possible that Env immune complexes can be found after boost. 
 
In summary, our findings on the influence of antigen and adjuvant components on the early 
innate responses after immunizations illustrate several critical steps on how responses to 
vaccines are developed and regulated. More knowledge on how the immune system can be 
manipulated to enhance the quality of adaptive responses is still needed. 
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5 CONCLUDING REMARKS 
The recent swine-flu pandemic, outbreaks of Ebola virus disease and the prevalence of 
malaria, tuberculosis and HIV infection are constant reminders of the need of novel vaccines 
as well as strategies to develop new vaccine platforms. Understanding how vaccines utilize 
the immune system to induce protective responses is central in vaccine development. 
Vaccines interact with the immune system for the first time at the site of administration and 
the immune responses initiated at the site most likely dictate the quantity and quality of 
adaptive immunity. In the two initial studies, we used clinical skin tests to model the local 
immune responses occurring after antigen delivery. By using, biopsies from positive 
indurations we found robust DC recruitment. Among the infiltrating DCs were the cross-
presenting CD141+ MDCs and PDCs, which are usually low or absent in normal skin. We 
found that HIV-1 infection influenced the magnitude of DC recruitment, which suggests 
dysfunctional mobilization of DCs to the skin. In the subsequent studies, we established a 
NHP model to study the local immune responses in vivo after intramuscular vaccination. This 
model enabled multiparametric phenotyping and enumeration of several immune cells 
including neutrophils and DCs after injection of fluorescently labeled HIV-1 Env together 
with the adjuvants MF59, alum or alum-TR7. We found distinct innate immune activation by 
these adjuvants. Although all adjuvants induced a rapid and transient mobilization of 
neutrophils, monocytes and DCs, alum-TLR7 induced robust DC activation and MF59 
specifically induced neutrophil homing to the LNs. Env+ DCs, monocytes and neutrophils 
were detected in the immunized muscle plus draining LNs. Side-by-side comparison of 
antigen presentation capacity ex vivo showed that Env+ MDCs were superior at inducing 
Env-specific CD4+ T cell proliferation. However, neutrophils were also capable of antigen 
presentation. Furthermore, both MF59 and alum-TLR7 were more efficient in priming of 
Env-specific T cells and inducing differentiation of Tfh cells and GC formations compared to 
the benchmark adjuvant alum. In summary, our approach to investigate the initial immune 
events at the site of antigen administration provide understanding of the basic mechanisms of 
vaccine responses, which may help tailoring of better vaccines 
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